Immunosuppressive materials and related methods
Zwitterionic phosphatidylserine monomers and polymers are developed to modulate immune responses and induce tolerance by directing immune cells away from inflammation, addressing the need for biocompatible materials that reduce nonspecific protein adsorption and inflammatory reactions.
Patent Information
- Application Number
- JP2024121095
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-03-23
- Filing Date
- 2024-07-26
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for improved biomaterials that exhibit non-fouling properties and can actively modulate immune responses to induce immune tolerance, particularly in inflammatory environments, while maintaining biocompatibility.
Development of zwitterionic phosphatidylserine (ZPS) monomers, polymers, and copolymers, which can be attached to particles or surfaces to impart immunosuppressive properties, utilizing their ability to direct immune cells towards an immunosuppressive phenotype.
The ZPS materials effectively reduce immune cell activation and secretion of inflammatory cytokines, promoting immune tolerance and reducing nonspecific protein adsorption, thereby enhancing biocompatibility and reducing inflammatory responses.
Smart Images

Figure 2024167192000037 
Figure 2024167192000038 
Figure 2024167192000039
Abstract
Description
Detailed Description of the Invention
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Application No. 62 / 647,534, filed March 23, 2018, which is expressly incorporated by reference in its entirety.
[0002] Government Licensing Rights This invention was made with government funding under Grant No. HDTRA1-13-1-0044 (Defense Threat Reduction Agency) and Grant No. DMR-1708436 (National Science Foundation). The Government has certain rights in this invention.
[0003] 2. Background of the Invention When considering biomaterials intended for in vivo applications, the first and most important requirement is biocompatibility with the human body. In addition to inert biomaterials, functional biomaterials that can actively control and modulate the immune response are also an approach. It has been found that apoptotic cells, by exposing phosphatidylserine (PS) on their surface, can direct immune cells, such as macrophages and dendritic cells, towards an immunosuppressive phenotype, thereby inducing immune tolerance even in areas of inflammatory activation.
[0004] There is a need for the development of improved non-fouling polymers having advantageous non-fouling properties, as well as compositions and materials containing such polymers. The present invention is directed to fulfilling this need and provides further related advantages.
[0005] Summary of the Invention The present invention provides zwitterionic phosphatidylserine (ZPS) monomers, ZPS polymers, and ZPS copolymers, methods of making such ZPS monomers, ZPS polymers, and ZPS copolymers, compositions and materials including the ZPS polymers and ZPS copolymers, and methods of using the ZPS monomers, ZPS polymers, and ZPS copolymers.
[0006] The present invention also provides non-zwitterionic (neutral) phosphatidylserine (NZPS) monomers, polymers, copolymers, compositions and materials comprising same, and methods of making and using same.
[0007] In one aspect, the present invention provides a particle comprising one or more zwitterionic phosphatidylserine polymers, the polymers being bound to the particle. In one embodiment, the particle has a microscale or nanoscale size and comprises one or more zwitterionic phosphatidylserine polymers bound to the particle. In certain embodiments, the polymer is covalently bound to the particle. In other embodiments, the polymer is physically adsorbed to the particle. As used herein, the term "microscale size" refers to a particle having a diameter of about 1 μm or more. As used herein, the term "nanoscale size" refers to a particle having a diameter of less than 1 μm.
[0008] In certain embodiments, the particle is a biomolecule, and the biomolecule modified to include the polymer is a bioconjugate. Exemplary biomolecules useful in the present invention include proteins, nucleic acids, glycoproteins, lipids, and proteoglycans. Exemplary proteins include enzymes, signaling proteins (e.g., hormones, cytokines, regulatory proteins, insulin, PD-1 / PD-L1 / 2 inhibitors), hemostatic or thrombosis proteins, and the like. These include proteins, vaccines, complement system proteins, and antibodies or functional fragments or characteristic portions thereof. In certain embodiments, the biomolecule is a pre-modified biomolecule, such as a PEGylated biomolecule (e.g., a protein modified to contain one or more poly(ethylene glycols)).
[0009] In other embodiments, the biomolecule is a small molecule therapeutic (a carbon-based therapeutic having a molecular weight of less than about 1000 g / mol, preferably less than about 800 g / mol).
[0010] In further embodiments, the particle is a drug delivery vehicle. Exemplary drug delivery vehicles include micelles, liposomes, and polymersomes (e.g., containing one or more therapeutic and / or diagnostic agents).
[0011] In certain embodiments, the particle is a cell, a virus, or a bacterium.
[0012] In other embodiments, the particles are hydrogels, such as microgels or nanogels.
[0013] In further embodiments, the particle is a metal, metal oxide, ceramic, synthetic polymer, natural polymer, crystal, semiconductor material, graphene, graphene oxide, iron oxide, or silica, or a quantum dot.
[0014] In certain embodiments, the particles have one or more zwitterionic phosphatidylserine polymers grafted thereto.In other embodiments, the particles have one or more zwitterionic phosphatidylserine polymers grafted thereto.
[0015] In certain embodiments, the particles have the formula:
[0016] [ka]
[0017] During the ceremony, * indicates the point of attachment of this repeat unit to another repeat unit in the polymer or copolymer, or an end group of the polymer or copolymer; B is the polymer backbone; L 2 wherein each x is an integer independently selected from 1 to 20; -(CH 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2) x -, -C(=O)OC(=O)O(CH 2 ) x -, -(CH 2 ) x -O-(CH 2 ) x - and -(CH 2 ) x -SS-(CH 2 ) x - is a linker group selected from R 2 and R 3 is hydrogen, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; m is an integer from 1 to 20; p is an integer from 1 to 20; and n is an integer from about 10 to about 500 The polymer comprises one or more zwitterionic phosphatidylserine polymers having a repeat unit of:
[0018] In other embodiments, the particles have the formula:
[0019] [ka]
[0020] During the ceremony, * indicates the point of attachment of this repeat unit to another repeat unit in the polymer or copolymer, or an end group of the polymer or copolymer; R 1 is hydrogen, fluorine, trifluoromethyl, cyano, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; R 2 and R 3 is hydrogen, C 1 -C 20 Alkyl, and C 6 -C12 aryl, or R 2 and R 3 forms a ring with the nitrogen; R 4 and R 5 is a polymerized residue of a polymerizable functional group; L is C or Si; L 2 wherein each x is an integer independently selected from 1 to 20; -(CH 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x -, -C(=O)OC(=O)O(CH 2 ) x -, -(CH 2 ) x -O-(CH 2 ) x - and -(CH 2 ) x -SS-(CH 2 ) x - is a linker group selected from L 3 and L 4 wherein each x is an integer independently selected from 0 to 20; -(CH 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x -, -C(=O)OC(=O)O(CH 2 ) x -, -(CH 2 ) x -O-(CH 2 ) x - and -(CH 2 ) x -SS-(CH 2 ) x - independently selected; m is an integer from 1 to 20; p is an integer from 1 to 20; and n is an integer from about 10 to about 500 The polymer comprises one or more zwitterionic phosphatidylserine polymers having a repeat unit of:
[0021] In a further embodiment, the particles have the formula:
[0022] [ka]
[0023] During the ceremony, * indicates the point of attachment of this repeat unit to another repeat unit in the polymer or copolymer, or an end group of the polymer or copolymer; R 1 is hydrogen, fluorine, trifluoromethyl, cyano, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; R 2 and R 3 is hydrogen and C 1 -C 6 alkyl, or R 2 and R 3 forms a ring with the nitrogen; X is O or NH; n is an integer from 1 to 20; m is an integer from 1 to 20; p is an integer from 1 to 20; and a is an integer from about 10 to about 500 The polymer comprises one or more zwitterionic phosphatidylserine polymers having a repeat unit of:
[0024] In another aspect, the invention provides a method for imparting immunosuppressive properties to a particle, hi one embodiment, the method comprises covalently attaching one or more zwitterionic phosphatidylserine polymers to the particle.
[0025] In another embodiment, the invention provides a substrate surface having one or more zwitterionic phosphatidylserine polymers covalently attached thereto.
[0026] In another aspect, the present invention also provides a particle having microscale or nanoscale dimensions, the particle comprising one or more neutral (non-zwitterionic) phosphatidylserine polymers covalently attached to the particle, and a method for imparting immunosuppressive properties to the particle, the method comprising: Also provided are methods that include covalently attaching one or more neutral (non-zwitterionic) phosphatidylserine polymers to particles, and substrate surfaces having one or more neutral (non-zwitterionic) phosphatidylserine polymers covalently attached thereto.
[0027] In a further aspect, the invention provides a ZPS monomer, in such an embodiment, the monomer comprises a polymerizable moiety covalently attached to a zwitterionic phosphatidylserine moiety.
[0028] In one embodiment, the ZPS monomer has the formula:
[0029] [ka]
[0030] During the ceremony, R 1 is hydrogen, fluorine, trifluoromethyl, cyano, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; R 2 and R 3 is hydrogen, C 1 -C 20 Alkyl, and C 6 -C 12 aryl, or R 2 and R 3 forms a ring with the nitrogen; R 4 and R5 are independently selected from functional groups suitable for polymerization by addition, condensation, or free radical polymerization; L is C or Si; L 2 In the formula, x is an integer of 1 to 20; -(CH 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x - independently selected; L 3 and L 4 wherein each x is an integer independently selected from 0 to 20; -(CH 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x -, -C(=O)OC(=O)O(CH 2 ) x -, -(CH 2 ) x -O-(CH 2 ) x - and -(CH 2 ) x -SS-(CH 2 ) x - independently selected; m is an integer from 1 to 20; and p is an integer from 1 to 20.
[0031] In another embodiment, the ZPS monomer has the formula:
[0032] [ka]
[0033] During the ceremony, R 1 is hydrogen, fluorine, trifluoromethyl, cyano, C 1 -C 20 Alkyl, and C 6 -C12 aryl; R 2 and R 3 is hydrogen and C 1 -C 6 alkyl, or R 2 and R 3 forms a ring with the nitrogen, X is O or NH; n is an integer from 1 to 20; m is an integer from 1 to 20, and p is an integer from 1 to 20.
[0034] In another aspect, the invention provides ZPS polymers and copolymers. In such embodiments, the ZPS polymer or copolymer has repeating units, and one or more of the repeating units comprises a zwitterionic phosphatidylserine moiety. In certain embodiments, the zwitterionic phosphatidylserine moiety is pendant from the polymer backbone. In other embodiments, the zwitterionic phosphatidylserine moiety is a component of the polymer backbone (e.g., a portion of the zwitterionic phosphatidylserine moiety is in the polymer backbone).
[0035] In certain embodiments, the ZPS polymer or copolymer has the formula:
[0036] [ka]
[0037] During the ceremony, * indicates the point of attachment of this repeat unit to another repeat unit in the polymer or copolymer, or an end group of the polymer or copolymer; B is the polymer backbone; L 2 is a linker group connecting the ZPS moiety to the scaffold, a representative group being -(CH 2 ) x-, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x -, -C(=O)OC(=O)O(CH 2 ) x -, -(CH 2 ) x -O-(CH 2 ) x - and -(CH 2 ) x -SS-(CH 2 ) x - Includes; R 2 and R 3 is hydrogen, C 1 -C 20 Alkyl, and C 6 -C 12 aryl, or R 2 and R 3 forms a ring with the nitrogen; m is an integer from 1 to 20; p is an integer from 1 to 20; and n is an integer from about 10 to about 500 Contains repeating units of the formula:
[0038] In other embodiments, the ZPS polymer or copolymer has the formula:
[0039] [ka]
[0040] During the ceremony, * indicates the point of attachment of this repeat unit to another repeat unit in the polymer or copolymer, or an end group of the polymer or copolymer; R 1 is hydrogen, fluorine, trifluoromethyl, cyano, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; R2 and R 3 is hydrogen, C 1 -C 20 Alkyl, and C 6 -C 12 aryl, or R 2 and R 3 forms a ring with the nitrogen; R 4 and R 5 are independently selected from the polymerizable residue of a functional group suitable for polymerization by addition, condensation, or free radical polymerization; L is C or Si; L 2 In the formula, x is an integer of 1 to 20; -(CH 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x - independently selected; L 3 and L 4 wherein each x is an integer independently selected from 0 to 20; -(CH 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x -, -C(=O)OC(=O)O(CH 2 ) x -, -(CH 2 ) x -O-(CH 2 ) x - and -(CH 2 ) x -SS-(CH 2 ) x - independently selected; m is an integer from 1 to 20; p is an integer from 1 to 20; and n is an integer from about 10 to about 500 Contains repeating units of the formula:
[0041] In a further embodiment, the ZPS polymer or copolymer has the formula:
[0042] [ka]
[0043] During the ceremony, * indicates the point of attachment of this repeat unit to another repeat unit in the polymer or copolymer, or an end group of the polymer or copolymer; R 1 is hydrogen, fluorine, trifluoromethyl, cyano, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; R 2 and R 3 is hydrogen and C 1 -C 6 alkyl, or R 2 and R 3 forms a ring with the nitrogen; X is O or NH; n is an integer from 1 to 20; m is an integer from 1 to 20; p is an integer from 1 to 20; and a is an integer from about 10 to about 500 Contains repeating units of the formula: Description of the drawings The above-referred aspects and many of the attendant advantages of the present invention will become more readily appreciated as the same become better understood by reference to the following detailed description and the accompanying drawings. [Brief description of the drawings]
[0044] [Figure 1] Comparison of relative fibrinogen adsorption (%) measured by ELSIA for MPC, NZPS, and ZPS hydrogel surfaces and a control, TCPS. [Figure 2A]Comparison of levels of TNF-α secretion into the supernatant, measured by ELISA, from RAW264.7 macrophages (105 cells / well) treated with various concentrations (10, 25, 50, 100, 200, 1000 μg / ml) of MPC, NZPS, or ZPS nanogel solutions for 18 hours, followed by stimulation with LPS (100 ng / mL) for 48 hours. [Figure 2B] Comparison of levels of TNF-α secretion into the supernatant, measured by ELISA, from RAW264.7 macrophages (105 cells / well) treated for 18 hours with MPC, NZPS, or ZPS nanogel solutions (100 μg / ml) that had been preincubated for 6 hours with various concentrations of Annexin V solutions (0, 10, 25, 50, 100, 200 μg / ml) and subsequently stimulated with LPS (100 ng / ml) for 48 hours. [Figure 2C] RAW264.7 macrophages (105 cells / well) were incubated with MPC, NZPS, and ZPS nanogels encapsulating FITC-BSA for 30, 60, 120, and 180 minutes, followed by washing and lysis of the cells and detection of the recovered fluorescence. [Figure 3A] Comparison of CD40 / CD80 staining for flow cytometry of DC2.4 dendritic cells incubated with native uricase, MPC-uricase, NZPS-uricase, and ZPS-uricase conjugate for 72 hours and blank control. (B) Summary of the percentage of immature (CD40- CD80-) dendritic cells. (C) Secretion of TGF-beta into the supernatant was detected by ELISA kit. [Figure 3B] Comparison of the percentage of dendritic cells that are immature (CD40- CD80-) for the dendritic cells depicted in FIG. 3A. [Figure 3C] Comparison of TGF-beta secretion, measured by ELISA, for dendritic cells described in FIG. 3A. [Figure 4A]4A-B are comparisons of the circulation times of native uricase, ZPS-uricase, NZPS-uricase, and MPC-uricase conjugates after the first (4A) and third (4B) injections in mice. [Figure 4B] 4A-B are comparisons of the circulation times of native uricase, ZPS-uricase, NZPS-uricase, and MPC-uricase conjugates after the first (4A) and third (4B) injections in mice. [Figure 4C] Detection of IgM (4C) and IgG (4D) specific for uricase or uricase conjugates is compared. On day 21, mice were sacrificed and serum was collected to detect IgM and IgG specific for uricase or uricase conjugates by ELISA test. [Figure 4D] Detection of IgM (4C) and IgG (4D) specific for uricase or uricase conjugates is compared. On day 21, mice were sacrificed and serum was collected to detect IgM and IgG specific for uricase or uricase conjugates by ELISA test. [Figure 4E] Flow cytometry staining of mouse CD4+ CD25+ splenocytes with Treg phenotype (Foxp3+) cells after 72 hours of treatment with native uricase, ZPS-uricase, NZPS-uricase, and MPC-uricase conjugate compared to blank control. Summary of percentage of Treg phenotype (Foxp3+) cells in CD4+ CD25+ splenocytes. [Figure 4F] The percentage of Tregs among CD4+ CD25+ cells from mice treated as described in FIG. 4E is compared.
[0045] Detailed Description of the Invention In one aspect, the present invention provides zwitterionic phosphatidylserine (ZPS) monomers, ZPS polymers, and ZPS copolymers, methods of making such ZPS monomers, ZPS polymers, and ZPS copolymers, compositions and materials including ZPS polymers and ZPS copolymers, and methods of using the ZPS monomers, ZPS polymers, and ZPS copolymers.
[0046] As used herein, the term "zwitterionic phosphatidylserine monomer" or "ZPS monomer" refers to a phosphatidylserine monomer that is 2 -CH(-CH 2 OP(=O)(O - ))-CO 2 H and its ionic form) and further cationic centers (e.g. For example -N + (R a )(R b )-, where R a and R b are independently H or C 1 -C 3 The term refers to a polymerizable monomer or pendant group of a homopolymer or copolymer that contains a N-alkyl group and a phosphate group that is an alkyl group. The monomer or pendant group of the homopolymer or copolymer is zwitterionic because it has a cationic center, N, and an anionic center, phosphate.
[0047] A representative ZPS monomer has the formula (I):
[0048] [ka]
[0049] In certain embodiments, R 1 is hydrogen, fluorine, trifluoromethyl, cyano, C 1 -C 20 Alkyl (preferably C 1 -C 6 alkyl), and C 6 -C 12aryl; R 2 and R 3 is hydrogen and C 1 -C 6 alkyl, or R 2 and R 3 together with the nitrogen form a ring, X is O or NH, n is an integer from 1 to 20 (e.g., 1, 2, 3, 4, 5, or 6), m is an integer from 1 to 20 (e.g., 1, 2, 3, 4, 5, or 6), and p is an integer from 1 to 20 (e.g., 1, 2, 3, 4, 5, or 6).
[0050] The term "zwitterionic phosphatidylserine polymer" or "ZPS polymer" refers to a polymer (i.e., homopolymer or copolymer) having one or more pendant groups that contain a phosphatidylserine moiety and further a cationic center, as described above. The polymer is zwitterionic due to the presence of a cationic N center and an anionic phosphate center in the repeat unit pendant group.
[0051] ZPS homopolymers are prepared by polymerization of monomers of formula (I), and ZPS copolymers are prepared by copolymerization of monomers of formula (I) with comonomers. Such ZPS polymers (homopolymers, random copolymers, block copolymers) contain repeat units with pendant zwitterionic phosphatidylserine (ZPS) moieties as shown below.
[0052] [ka]
[0053] In certain embodiments, R 1 , R 2 , R 3, X, n, m, and p are as described above for monomers of formula (I), a is an integer from about 10 to about 500, and * indicates the point of attachment of this repeat unit to other repeat units in the polymer or copolymer, or an end group of the polymer or copolymer.
[0054] As described herein, the ZPS monomers can be readily polymerized under standard polymerization conditions to provide ZPS polymers.
[0055] ZPS Monomers, ZPS Polymers, and ZPS Copolymers In certain embodiments, the present invention provides ZPS monomers, and ZPS polymers and copolymers prepared from the ZPS monomers.
[0056] Monomers according to the present invention include (a) ZPS monomers having backbones selected from silicone, fluorinated, peptide, urethane, urea, imide, carbonate, anhydride, phosphazene, epoxy, sulfone, and sulfide backbones, and degradable backbones other than methacrylate and acrylate backbones, or (b) linear ZPS crosslinkers, degradable and non-degradable ZPS-based crosslinkers, or (c) linear ZPS-based monomers that provide ZPS groups in the polymer backbone or in the polymer side chains.
[0057] Polymers and copolymers according to the invention include homopolymers, random copolymers, block copolymers, multiblock copolymers, and branched or star polymers that contain repeat units containing ZPS groups, including polymers prepared from the polymerization (or copolymerization) of one or more monomers according to the invention (e.g., ZPS monomers).
[0058] ZPS Monomers. In one aspect, the present invention provides ZPS monomers. ZPS monomers are used to form ZPS polymers and ZPS copolymers that contain repeating units that contain ZPS. The ZPS groups of the repeat units and polymers may be pendant ZPS groups (i.e., polymer side chains).
[0059] In certain embodiments, a ZPS monomer comprises a polymerizable moiety covalently linked to a zwitterionic phosphatidylserine moiety.
[0060] In certain embodiments, the ZPS monomers include monomers that provide polymers or copolymers with pendant ZPS groups (polymeric side chains). Exemplary ZPS monomers have formula (I) as described above. Other exemplary ZPS monomers have formula (III).
[0061] [ka]
[0062] During the ceremony, R 1 is hydrogen, fluorine, trifluoromethyl, cyano, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; R 2 and R 3 is hydrogen, C 1 -C 20 Alkyl (e.g., C 1 -C 3 alkyl), and C 6 -C 12 aryl, or R 2 and R 3 forms a ring with the nitrogen; R 4 and R 5 are independently selected from functional groups suitable for polymerization by addition, condensation, or free radical polymerization; L is C or Si; L 2 -(CH) -(CH) -(CH)2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x - independently selected; L 3 and L 4 wherein each x is an integer independently selected from 0 to 20, preferably 1 to 20 (in certain embodiments, L 3 and / or L 4 does not exist), -(CH 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x -, -C(=O)OC(=O)O(CH 2 ) x -, -(CH 2 ) x -O-(CH 2 ) x - and -(CH 2 ) x -SS-(CH 2 ) x - independently selected; m is an integer from 1 to 20 (e.g., 1, 2, 3, 4, 5, or 6); and p is an integer from 1 to 20 (e.g., 1, 2, 3, 4, 5, or 6).
[0063] The preparation of representative ZPS monomers useful in making polymers and copolymers according to the present invention is described in Example 1.
[0064] It is understood that the ZPS polymers and copolymers of the present invention used in making the surface coatings, bulk materials, carrier materials, hydrogels, and conjugates of the present invention can be prepared from the monomers described herein, including the methacrylate / methacrylamide ZPS monomers of formula (I) and the ZPS monomers of formula (III).
[0065] ZPS Polymers and Copolymers In another aspect, the present invention provides ZPS polymers prepared from ZPS monomers as described herein and comprising ZPS repeat units.
[0066] In certain embodiments, a ZPS polymer or copolymer has repeating units, and one or more of the repeating units comprises a zwitterionic phosphatidylserine moiety. In certain of these embodiments, the zwitterionic phosphatidylserine moiety is pendant from the polymer backbone. In other of these embodiments, the zwitterionic phosphatidylserine moiety is a component of the polymer backbone (e.g., a portion of the zwitterionic phosphatidylserine moiety is in the polymer backbone).
[0067] In certain embodiments of such polymers and copolymers, the backbone of the polymers and copolymers may be any one of a polyester, a polypeptide, a polyimide, a polyphosphazene, a polysiloxane, a polyepoxy, a vinyl polymer, a phenolic polymer, a polyurethane, a polyurea, a polycarbonate, a polysulfone, or a polysulfide.
[0068] The ZPS polymers and copolymers of the present invention include those prepared from monomers of formula (I) and (III). The polymers can be formed by polymerization of (a) a monomer of formula (I), (b) a monomer of formula (III), or (c) a comonomer of formula (I) and (III). The copolymers can be prepared by (a) copolymerization of a monomer of formula (I) with a second comonomer suitable for copolymerization with the monomer of formula (I), (b) copolymerization of a monomer of formula (III) with a second comonomer suitable for copolymerization with the monomer of formula (II), and (c) copolymerization of a monomer of formula (I) with a monomer of formula (III) suitable for copolymerization with the monomer of formula (I).
[0069] In certain embodiments, the ZPS monomer provides a polymer repeat unit that includes a ZPS moiety pendant from the polymer backbone (i.e., forming part of a polymer side chain). A representative polymer having a ZPS moiety pendant from the polymer backbone has formula (II) as described above. Another representative ZPS polymer has formula (IV).
[0070] [ka]
[0071] During the ceremony, * indicates the point of attachment of this repeat unit to another repeat unit in the polymer or copolymer, or an end group of the polymer or copolymer; B is the polymer backbone described above; L 2 is a linker group connecting the ZPS moiety to the scaffold, a representative group being -(CH 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x -, -C(=O)OC(=O)O(CH 2 ) x -, -(CH 2 ) x -O-(CH 2 ) x - and -(CH 2 ) x -SS-(CH 2 ) x - Includes; R 2 and R 3 is hydrogen, C 1 -C 20 Alkyl (e.g., C 1 -C 3 Alkyl;C 3 -C 7 (including cyclic alkyl such as cycloalkyl), and C 6 -C12 aryl, or R 2 and R 3 forms a ring with the nitrogen; m is an integer from 1 to 20 (e.g., 1, 2, 3, 4, 5, or 6); p is an integer from 1 to 20 (e.g., 1, 2, 3, 4, 5, or 6); and n is an integer of about 10 to about 500.
[0072] In another embodiment, an exemplary polymer having ZPS moieties pendant from the polymer backbone has the formula (V):
[0073] [ka]
[0074] In the formula, R 1 , R 2 , R 3 , R 4 , R 5 , L, L 2 , L 3 , L 4 , m, p, and * are as described above for the monomer of formula (III), and R 4 and R 5 is the functional group R in formula (III) 4 and R 5 and n is an integer of about 10 to about 500.
[0075] In certain embodiments, the zwitterionic phosphatidylserine moieties of the ZPS polymer are contained, at least in part, in the polymer backbone.
[0076] In certain of these embodiments, the ZPS polymer has repeat units comprising the formula:
[0077] [ka]
[0078] In the formula, L 2 , p, and * are as described above for the polymer of formula (IV), and L 2 is bonded to B at N + (R 1 ) of nitrogen (i.e., L 2 is understood to be an atom in B to which is covalently bonded; and n is an integer of from about 10 to about 500.
[0079] In other of these embodiments, the ZPS polymer comprises a repeating group having the formula: and has units.
[0080] [ka]
[0081] In the formula, R 1 , R 4 , R 5 , L 2 , L 3 , L 4 , p, and * are as described above for the monomer of formula (III), and R 4 and R 5 is the functional group R in formula (III) 4 and R 5 and n is an integer of about 10 to about 500.
[0082] In certain embodiments, the invention provides modified surfaces comprising a polymer of formula (II), (IV), (IVA), (V), or (VA). The modified surface may be the surface of an artificial nervous system, a neuronal regeneration platform, a neural sensor, a cell culture platform; a non-fouling semiconductor, a battery, an organic solar cell, a biofuel cell, a printed electronic circuit, an organic light emitting diode, an actuator, an electrochromic device, a supercapacitor, a chemical sensor, a flexible transparent display, an electromagnetic shield, an antistatic coating, a microwave absorbing device, or a radar absorbing device.
[0083] In certain embodiments, the present invention provides bulk constructs comprising polymers of formula (II), (IV), (IVA), (V), or (VA). Exemplary constructs may be medical, electronic, or marine devices. In certain of these embodiments, the bulk constructs are artificial nervous systems, neuronal regeneration platforms, neural sensors, cell culture platforms; non-fouling semiconductors, batteries, organic solar cells, biofuel cells, printed electronic circuits, organic light-emitting diodes, actuators, electrochromic devices, supercapacitors, chemical sensors, flexible transparent displays, electromagnetic shields, antistatic coatings, microwave absorbing devices, or radar absorbing devices.
[0084] ZPS Star Polymers and Copolymers In another aspect, the present invention provides ZPS star polymers and ZPS copolymers that contain ZPS repeat units.
[0085] Such polymers include a core and multiple ZPS branches covalently attached to the core. The core of such polymers may be a star-shaped small molecule, oligomer, or polymer. In certain embodiments, such polymers may include three, four, five, or more ZPS branches. In certain of these embodiments, one or more of the ZPS branches may themselves be further branched. In certain embodiments, such polymers may further include terminal functional groups attached to the ends of multiple ZPS branches. Representative terminal functional groups are OH, NH, and NH 2 , S.H., N. 3 , CH=CH 2 , C≡CH, COOH, CHO, imidoester, haloacetyl, hydrazide, alkoxyamine, arylazide, diazirine, maleimide, carbodiimide, N-hydroxysuccinimide (NHS), thiazolidine-2-thione, pyridyl disulfide, difluorinatedcyclooctyne, Staudinger's reagent (pair of two), isocyanate, isothiocyanate, thioether, sulfhydryl, hydrazine, hydroxymethylphosphine, sulfo-NHS ester, pentafluorophenyl ester, sulfonyl azide, and 5H-dibenz[b,f]azepine, and derivatives thereof.
[0086] ZPS Copolymers: Hydrophobic and Hydrophilic Building Blocks In a further aspect, the present invention provides ZPS copolymers comprising ZPS repeat units and hydrophobic and / or hydrophilic building blocks.
[0087] In certain embodiments, the copolymer is a random, diblock, or hyperbranched copolymer containing ZPS repeat units (eg, poly(ZPS)).
[0088] Representative block copolymers include at least one ZPS building block (A) and at least one hydrophobic block (B). In certain embodiments, the copolymer further includes a hydrophilic block (C) or a second hydrophobic block (C). Block copolymers according to the invention include AB diblock copolymers, ABC triblock copolymers, ABA triblock copolymers, BAB triblock copolymers, linear or star multiblock (AB) copolymers, and the like. n Copolymer, Miktoarm Block Copolymer (AB n Or A n B), and mixtures thereof. In certain embodiments, the copolymer further comprises neutral hydrophilic repeat units (e.g., alkylene oxide repeat units, such as ethylene oxide repeat units).
[0089] In certain embodiments, the copolymer comprises a ZPS component comprising repeat units derived from a ZPS monomer (e.g., a ZPS monomer of the present invention having formula (I) or (III)) and a hydrophobic component comprising repeat units derived from a hydrophobic monomer.
[0090] Representative hydrophobic repeat units may be derived from acrylic acids and esters, alkylacrylic acids and esters, acrylamides, alkylacrylamides, polysiloxane repeat units, polyester repeat units, polyurethane repeat units, polystyrene repeat units, and fluorinated derivatives thereof.
[0091] In certain embodiments, the copolymer comprises a ZPS component comprising repeat units derived from a ZPS monomer (e.g., a ZPS monomer of the present invention having formula (I) or (III)), a hydrophilic component comprising repeat units derived from a hydrophilic monomer, and, optionally, a hydrophobic component comprising repeat units derived from a hydrophilic monomer. In certain of these embodiments, the hydrophilic repeat units comprise a ZPS moiety. In other embodiments, the hydrophilic repeat unit may be polyhydroxyethyl methacrylate (PHEMA), polyethylene glycol (PEG), polycarboxybetaine (PCB), polysulfobetaine (PSB), polyphosphobetaine (PPB), polyphosphorylcholine (PPC), polyacrylamide (PAA), poly(2,3-dihydroxypropyl methacrylate) (PDHPM), poly(N-isopropylacrylamide) (PNIPAM), polyacrylamide (PAM), poly(2-oxazoline), poly(acrylic acid), polymethacrylate (PMA), poly(vinyl alcohol) (PVA), poly(vinylpyrrolidone) (PVP), polyelectrolytes, polysaccharides, polyamides, and various hydrophilic polymers, peptide-based materials, and copolymers of two or more hydrophilic monomers.
[0092] ZPS polymers for surface coatings, bulk materials, and individual materials In other aspects, the present invention provides ZPS polymer surface coatings, ZPS polymer bulk materials, and ZPS polymer monolayer materials. In certain embodiments, the ZPS polymer surface coatings, bulk materials, and monolayer materials are prepared from ZPS monomers and polymers and copolymers prepared from ZPS monomers.
[0093] ZPS polymers can be attached to surfaces (e.g., medical devices, sensors, membranes, ships, and marine structures) by "graft-from" or "graft-to" techniques to render the surfaces non-fouling. ZPS polymers can also be mixed with or into bulk materials (e.g., silicones). Surface coatings can be applied to flat or nano / microparticle surfaces. ZPS polymers can also be used to create stand-alone low-fouling and high-strength materials and devices for medical and marine applications due to their (i) unique backbones such as silicone, fluorinated, urethane, imide, amide, etc., and (ii) strong interactions such as multiple hydrogen bonds, and (iii) interpenetrating networks.
[0094] Surface coating with ZPS polymers. The present invention provides surface coating with ZPS polymers. In certain embodiments, the surface coating comprises a ZPS polymer (oligomer) or ZPS copolymer according to the invention described herein (e.g., a polymer of formula (II), (IV), (IVA), (V), or (VA)).
[0095] Surfaces coated with ZPS polymers and copolymers have non-fouling properties. The non-fouling properties of a surface can be assessed by fibrinogen adsorption and cell adhesion. In a specific embodiment, the surfaces of the present invention have a fibrinogen adsorption of about 200 ng / cm 2 In another embodiment, the surfaces of the present invention have a fibrinogen adsorption of less than about 100 ng / cm 2 In a further embodiment, the surface of the present invention has a fibrinogen adsorption of less than about 50 ng / cm 2 In another embodiment, the surfaces of the present invention have a fibrinogen adsorption of less than about 30 ng / cm 2 In a further embodiment, the surface of the present invention has a fibrinogen adsorption of less than about 20 ng / cm 2 In another embodiment, the surfaces of the present invention have a fibrinogen adsorption of less than about 10 ng / cm2 In certain embodiments, the surfaces of the present invention have a fibrinogen adsorption of less than about 5 ng / cm 2 is less than.
[0096] In certain embodiments, the surface is coated with a ZPS polymer or copolymer prepared from one or more ZPS monomers selected from polymerizable groups including, but not limited to, ZPS acrylates, ZPS acrylamides, ZPS methacrylates, ZPS methacrylamides, ZPS vinyl compounds, ZPS epoxides, and mixtures thereof. Representative ZPS monomers include those described herein, including the ZPS monomers of formulas (I) and (III).
[0097] In certain embodiments, the ZPS polymer or copolymer is a random, multiblock, or hyperbranched copolymer, including poly(ZPS). In other embodiments, the ZPS polymer or copolymer is an interpenetrating ZPS polymer network.
[0098] In certain embodiments, the ZPS polymer or copolymer has surface attachment groups (eg, DOPA, thiol, silane, click chemistry, hydrophobic, hydrophilic, and charged groups).
[0099] Surfaces coated with ZPS polymers and copolymers exhibit covalent interactions The ZPS polymers or copolymers can be prepared by attaching them to the substrate surface through physical hydrophobic, charge-charge and hydrogel bonding interactions, or through a combination of such chemical and physical interactions.
[0100] A surface coated with a ZPS polymer or copolymer can be prepared by grafting a ZPS polymer from a substrate surface (e.g., preparing a polymer surface by polymerizing suitable monomers in the presence of a substrate to form a polymer or copolymer) or by grafting a ZPS polymer to a substrate surface (e.g., preparing a polymer surface by attaching a preformed polymer or copolymer to a substrate).
[0101] In certain embodiments, ZPS polymers and copolymers are grafted from the substrate by polymerization techniques such as atom transfer radical polymerization (ATRP), reversible addition-fragmentation chain transfer polymerization (RAFT), or photoinferter polymerization.
[0102] In certain embodiments, ZPS polymers and copolymers are grafted to substrates by conjugation methods such as click chemistry, DOPA conjugation chemistry, or thiol- or silane-based self-assembled monolayers (SAMs).
[0103] Surface coatings with ZPS polymers can be applied to a variety of substrates (e.g., substrate surfaces). In certain embodiments, the surface is all or part of a biomedical device. Exemplary biomedical devices include catheters, ear drainage tubes, feeding tubes, glaucoma drainage tubes, hydrocephalous shunts, corneal prostheses, nerve guidance tubes, tissue adhesives, x-ray conduits, artificial joints, artificial heart valves, artificial blood vessels, pacemakers, left ventricular assist devices (LVADs), arterial grafts, vascular grafts, stents, intravascular stents, heart valves, joint replacements, vascular prostheses, skin repair devices, cochlear replacements, contact lenses, artificial ligaments and tendons, dental implants, and tissue scaffolds in tissue engineering. In certain embodiments, the device is a contact lens.
[0104] In certain embodiments, the surface is the whole or a part of a particle. Exemplary particles include particles of metals, metal oxides, ceramics, synthetic polymers, natural polymers, silicon dioxide, crystals, and semiconductor materials. In certain embodiments, the particle is a biomolecule, such as a protein (e.g., an enzyme) or a nucleic acid (e.g., DNA or RNA). In other embodiments, the particle is a cell.
[0105] In certain embodiments, the surface is all or part of a membrane or bioseparation membrane. Exemplary membranes include those used in protein purification, wastewater treatment, bioreactors, seawater desalination, and water / oil purification.
[0106] In certain embodiments, the surface contacts or forms the entirety of a drug delivery vehicle, such as a gene delivery vehicle, an RNA delivery vehicle, or a protein delivery vehicle.
[0107] In certain embodiments, the surface is in contact with or forms all or part of an implantable or subcutaneous sensor.
[0108] In certain embodiments, the surface is in contact with all or a portion of a tissue scaffold. forming or forming
[0109] ZPS Polymer Bulk Materials. The present invention provides ZPS polymer bulk materials. In certain embodiments, the bulk materials comprise ZPS polymers (oligomers) or ZPS copolymers according to the invention described herein (e.g., polymers of formula (II), (IV), (IVA), (V), or (VA)). In certain embodiments, the materials are prepared by a polymerization or copolymerization process using monomers according to the invention described herein (e.g., monomers of formula (I) or (III)).
[0110] In certain embodiments, the bulk material is obtained by blending one or more ZPS polymers or copolymers with one or more other polymers, such as polyesters, polycarbonates, polyurethanes, polyureas, polysulfides, polysulfones, polyimides, polyepoxies, aromatic polyesters, cellulosics, fluoropolymers, polyacrylics, polyamides, polyanhydrides, polyethers, vinyl polymers, phenolics, elastomers, and other addition polymers.
[0111] In other embodiments, the bulk material comprises an interpenetrating ZPS polymer network and one or more other polymers, such as polyesters, polycarbonates, polyurethanes, polyureas, polysulfides, polysulfones, polyimides, polyepoxies, aromatic polyesters, cellulosics, fluoropolymers, polyacrylics, polyamides, polyanhydrides, polyethers, vinyl polymers, phenolics, elastomers, and other addition polymers.
[0112] ZPS Polymer Monolithic Materials. The present invention provides ZPS polymer monolithic materials. In certain embodiments, the materials comprise ZPS polymers (oligomers) or ZPS copolymers according to the invention described herein (e.g., polymers of formula (II), (IV), (IVA), (V), or (VA)). In certain embodiments, the materials are prepared by a polymerization or copolymerization process using monomers according to the invention described herein (e.g., monomers of formula (I) or (III)).
[0113] In certain embodiments, the ZPS polymer carrier material is a non-fouling material and has high mechanical strength. In certain of these embodiments, the carrier material has a protein adsorption of about 30 ng / cm 2 Less than 50ng / cm 2 Less than or about 100 ng / cm 2 and a tensile / compressive strength greater than about 0.2 MPa, greater than about 0.5 MPa, or greater than about 1.0 MPa.
[0114] In certain embodiments, the ZPS polymer free-molecular material has dipole-dipole interactions, such as (a) cyano groups (C≡N) and (b) amide groups (-(NH)-(C=O)-), multiple amide groups ((-(NH)-(C=O)-) n (n=1~5)), urethane group (-(NH)-(C=O)-O-), multiple urethane groups ((-(NH)-(C=O)-O-) n (n=1~5)), urea group (-(NH)-(C=O)-(NH)-), multiple urea groups ((-(NH)-(C=O)-(NH)-) n ZPS polymer networks are reinforced by the incorporation of hydrogen donors / acceptors such as aryl, ...
[0115] ZPS polymer networks are made up of ZPS monomers or polyacrylates, polymethacrylates, polyacrylamides, polymethacrylamides, polyamides, polydimethylsiloxanes, polyethylenes, polypropylenes, polystyrenes, polytetrafluoroethylenes, etc. The ZPS polymer network may be reinforced with backbones in the ZPS polymer such as olefins, polyisobutenes, polyesters, polycarbonates, polyurethanes, polyureas, polysulfides, polysulfones, polyimides, polyepoxies, polyanhydrides, polyethers, and other condensation / addition polymers. In certain embodiments, the ZPS polymer network is reinforced with any combination of the above.
[0116] In certain embodiments, ZPS polymers may form copolymers with other polymers or composites such as polyesters, polycarbonates, polyurethanes, polyureas, polysulfides, polysulfones, polyimides, polyepoxies, aromatic polyesters, cellulosics, fluoropolymers, polyacrylics, polyamides, polyanhydrides, polyethers, vinyl polymers, phenolics, elastomers, and other addition polymers. Fibers, clays, nanotubes, and other inorganic objects may be added to increase the mechanical properties of these materials.
[0117] The ZPS monolithic material of the present invention may be subjected to a variety of processes to form objects, such as injection molding, blow molding, extrusion molding, calendar molding, casting, compression molding, prevarication molding, and 3D printing.
[0118] The ZPS free-standing materials of the present invention can be used in biomedical / bioengineering applications, consumer product applications, engineering / marine applications, therapeutic / diagnostic applications such as catheters, ear drainage tubes, feeding tubes, glaucoma drainage tubes, hydrocephalous shunts, corneal prostheses, nerve guidance tubes, tissue adhesives, x-ray conduits, artificial joints, artificial heart valves, artificial blood vessels, pacemakers, left ventricular assist devices (LVADs), arterial grafts, vascular grafts, stents, endovascular stents, heart valves, replacement joints, vascular prostheses, skin repair devices, replacement cochleae, contact lenses, artificial ligaments and tendons, dental implants, and tissue scaffolds in regenerative tissue engineering, drug delivery, gene delivery, RNA delivery, protein delivery, marine and engineering devices / objects (e.g., membranes, tubes, pipes, vessels, or plates).
[0119] In certain embodiments, the monolithic materials can be used in marine products such as marine vessel hulls, marine structures, bridges, propellers, heat exchangers, periscopes, sensors, fishing nets, cables, tubes / pipes, vessels, membranes, and oil booms.
[0120] In certain embodiments, the carrier material may be conjugated to a biomaterial. Exemplary biomaterials include nucleic acids (e.g., genes, DNA, RNA), proteins (e.g., enzymes, antibodies or functional fragments thereof), peptides, lipids, cells or microorganisms, solid nanoparticles (iron oxide, silica, quantum dots, or gold nanoparticles), or are used to protect the skin from dehydration by surfactants.
[0121] ZPS polymer hydrogel The present invention provides hydrogels of ZPS polymers. In certain embodiments, the hydrogels comprise crosslinked ZPS polymers (oligomers) or ZPS copolymers according to the invention described herein (e.g., polymers of formula (II), (IV), (IVA), (V), or (VA)). In certain embodiments, the hydrogels are prepared by a polymerization or copolymerization process using monomers according to the invention described herein (e.g., monomers of formula (I) or (III)).
[0122] ZPS polymer hydrogels can be made from ZPS monomers and a variety of crosslinkers, including degradable and non-degradable ZPS crosslinkers. ZPS star polymers can be prepared by forming hydrogels (e.g., by click chemistry). The hydrogels can be in the form of bulk hydrogels or pellet hydrogels. These hydrogels can be used as implantable materials and devices to reduce capsule formation and as media to protect, grow, preserve, and differentiate various cells (e.g., stem cells, immune cells, islets, platelets, and cardiomyocytes) in a controlled manner. Pellet and star hydrogels can be injected with biologics (e.g., various cells, and tumors for tumor vaccines).
[0123] In certain embodiments, the ZPS hydrogels are crosslinked hydrogels prepared from one or more ZPS monomers (eg, monomers of formula (I) or (II)) using one or more crosslinking agents.
[0124] In others of these embodiments, the crosslinker is a polyfunctional zwitterionic crosslinker that contains a carboxybetaine, sulfobetaine, or phosphobetaine moiety.
[0125] In further of these embodiments, the crosslinker is a multifunctional crosslinker, such as N,N'-methylenebisacrylamide (MBAA), polyethylene glycol (PEG) diacrylate or diacrylamide, or PEG dimethacrylate or dimethacrylamide.
[0126] In certain embodiments, the hydrogels are prepared using bifunctional ZPS crosslinkers. In other embodiments, the hydrogels are prepared using degradable or non-degradable crosslinkers. In further embodiments, the hydrogels are prepared using degradable zwitterionic disulfide crosslinkers. In other embodiments, the hydrogels are prepared using peptide-based crosslinkers that can be degraded by enzymes or suitable agents.
[0127] The ZPS hydrogels of the present invention can be prepared by free radical mediated polymerization techniques such as thermal polymerization, photopolymerization, or redox polymerization.
[0128] The preparation of a representative ZPS hydrogel according to the present invention is described in Example 4. Protein adsorption and cell adhesion to a representative ZPS hydrogel is described in Example 4.
[0129] The ZPS hydrogels of the present invention can be used in biosensors and biomedical devices, vascular grafts, intravascular stents, heart valves, replacement joints, cell storage / growth / differentiation, drug delivery platforms, ship hulls, marine structures / instruments, and other materials and devices that come into contact with physiological environments.
[0130] In certain embodiments, the ZPS hydrogel is a star hydrogel. Star hydrogels can be prepared from a polymer having a core and multiple ZPS-based or zwitterionic branches covalently attached to the core. Exemplary cores include one of the star-shaped small molecules, oligomers, or polymers with three, four, five, or more branches.
[0131] In certain embodiments, the hydrogel is crosslinked by a degradable crosslinker that can be selectively degraded (i.e., under certain conditions). The degradable crosslinker may be selected from peptide crosslinkers, polysaccharide crosslinkers, anhydride crosslinkers, disulfide crosslinkers, and polyester crosslinkers. For certain of these embodiments, the hydrogel can be hydrolyzed or digested by enzymes.
[0132] In certain embodiments, star hydrogel branched polymers have terminal functional groups attached to the ends of the branches (eg, the ends of multiple ZPS or zwitterionic branches). Representative terminal functional groups are OH, NH, and NH 2 , S.H., N. 3 , CH=CH 2 , C≡CH, COOH, CHO, imidoesters, haloacetyls, hydrazides, alkoxyamines, aryl azides, diazirines, maleimides, carbodiimides, N-hydroxysuccinimide (NHS), thiazolidine-2-thiones, pyridyl disulfides, difluorocyclooctynes, Staudinger's reagents (pairs of two), isocyanates, isothiocyanates, thioethers, sulfhydryls, hydrazines, hydroxymethylphosphines, sulfo-NHS esters, pentafluorophenyl esters, sulfonyl azides, and 5H-dibenz[b,f]azepines.
[0133] In certain embodiments, the hydrogel comprises a first polymer / copolymer (first star hydrogel) conjugated to one or more second polymers / copolymers (second star hydrogels). The hydrogel can be used as an injectable hydrogel. In certain of these embodiments, the first polymer is conjugated to one or more second polymers by terminal functional groups.
[0134] The star hydrogels can be combined with zwitterionic hydrogels and formed into pellets of various sizes in a specific mold or by mechanical reduction (e.g., in a blender). These pellet hydrogels can be used as injectable hydrogels with or without biological content.
[0135] The ZPS star hydrogels of the present invention can be prepared by (a) synthesizing ZPS or zwitterionic branches by ATRP, RAFT, ROP, condensation, Michael addition, branch generation / extension reactions, and (b) reacting the ZPS or zwitterionic branches with a core to obtain a star polymer. In certain embodiments, the method further comprises functionalizing the ends of the ZPS or zwitterionic branches by "click" reactions, thiol exchange reactions, or reduction reactions.
[0136] In a particular embodiment, the ZPS hydrogel is a microgel. The microgels of the present invention are micron-sized, with dimensions of about 1 micron (10 -6 m)~1mm(10 -2 m), which is a cross-linked hydrogel composed of ZPS-based monomers and supported by any cross-linking chemistry.
[0137] The microgels of the present invention can be prepared in a variety of ways using functionalized ZPS monomers, oligomers, or polymers, (a) one of the reactive pairs selected from an azide and an alkyne, an azide and an alkene, a thiol and a maleimide, a thiol and an alkene, a thiol and a disulfide, or any other "click" type pair, a bioorthogonal pair, or other reactive pair; (b) located at the termini or along the backbone of the polymer structure; (c) can be prepared by methods including the incorporation of peptides, nucleic acids, proteins, antibodies, nanoparticles, microparticles, micelles, liposomes, polymersomes, drugs, drug precursors, or other therapeutic species or drug delivery modalities for surgical, therapeutic, wound healing applications, drug delivery preparations, cell storage and preservation, or regenerative medicine purposes.
[0138] In certain embodiments, the microgels comprise mixtures of ZPS monomers or polymers with other types of ionic or non-ionic non-fouling monomers or polymers, or copolymers of ZPS-based polymers with other types of ionic or non-ionic monomers.
[0139] For the microgels, crosslinking can be achieved using any combination of physical and / or chemical mechanisms, which in certain embodiments include: (a) Chemical crosslinkers of any structure that copolymerizes with monomers through radical-mediated reactions, including commercially available crosslinkers based on polyethylene glycol (PEG), oligoethylene glycol (OEG), or other structures or groups and having two or more terminal acrylate, methacrylate, acrylamide, maleimide, or similar reactive groups, or custom-synthesized crosslinkers incorporating any functional, reactive, or degradable group (the degradable group can optionally be selected from disulfide bonds, esters, anhydrides, enzyme-cleavable peptides (such as the GPQGIWCG motif), or external stimuli-responsive chemical species); (b) bioorthogonal crosslinkable and "click" species, such as azide / alkyne (including SPAAC) and thiol-ene species, either included as functional groups in the polymer backbone or structure or present as separate crosslinkable molecules; (c) any type of physical interaction, including ionic interactions, hydrogen bonds, hydrophobic interactions, interactions with biomolecules or with nanoparticles of natural or synthetic origin, or any other reversible or irreversible physical interaction; and (d) Any combination of the cross-linking mechanisms described above.
[0140] In certain embodiments, the microgels are prepared using bifunctional ZPS crosslinkable molecules, oligomers, or polymers incorporating one or more ZPS moieties, or mixtures of such molecules.
[0141] In certain embodiments, the microgels are prepared using zwitterionic (carboxybetaine, sulfobetaine, or phosphobetaine) crosslinking molecules, oligomers, or polymers, or mixtures of such molecules, that incorporate one or more zwitterionic sites. Such crosslinkers may incorporate disulfide bonds, esters, or stimuli-responsive groups, or degradable groups such as degradable peptides.
[0142] In certain embodiments, the invention provides bulk materials formed from an assembly of two or more microgels as described above, which have unique properties due to interactions between the individual microgels, and which may contain other components such as small molecule drugs, peptides, biomolecules, nanoparticles, cells, or tissues.
[0143] In certain embodiments, the microgels and aggregates described above are made from microgels that are limited in size due to the polymerization method (eg, microemulsion polymerization).
[0144] In another embodiment, the microgels are (bulk) hydrogels as described above or star hydrogels as described above that have been subjected to additional sizing after polymerization to limit the size of the individual units, i.e., by grinding, extruding, chopping, cutting or pelletizing the hydrogel through optional processing steps.
[0145] The microgels and aggregates described above may be dried or lyophilized (freeze-dried) into a dehydrated powder for storage, transportation, use, or sterilization purposes. The microgel powder may be rehydrated with any aqueous fluid, including water, saline, or ionic solutions, cell growth or storage media with or without cells, or any other physiologically relevant solution that may contain therapeutic drugs, therapeutic proteins, therapeutic nucleic acids, cells, nanoparticles, or microparticles.
[0146] The ZPS star hydrogels and microgels, as well as assemblies thereof and / or compositions obtained by partially or completely drying or rehydrating them, have the following uses: (a) materials that have non-Newtonian behavior (e.g., exhibiting viscoelastic, rheopexy, thixotropic, shear thickening (dilatancy), shear thinning (pseudoplastic), and / or Bingham plasticity properties); (b) self-healing and / or shape-memory or similar types of "smart" materials capable of repairing damage or regaining properties after damage or external stimuli; and (c) Anti-fouling materials or surface coatings for preventing non-specific adsorption of proteins or other biomolecules, e.g., for marine applications, drug delivery platforms, biosensors and other medical devices, vascular grafts, intravascular stents, heart valves, replacement joints, and other materials and devices in contact with the physiological environment.
[0147] ZPS star hydrogels and microgels and their assemblies can be used as injectable or spreadable materials in biomedical applications, especially those requiring non-Newtonian fluid properties and high biocompatibility: (a) injectable or topical materials capable of providing mechanical assistance, such as those used in cosmetic or reconstructive surgery, vascular prostheses, skin repair devices, replacement cochleae, injectable vitreous materials, artificial cartilage, artificial fat, collagen mimetics, and other soft tissue mimetics or aids; (b) injectable or paintable materials that have a desired or specific biological interaction with a surface or tissue, particularly where non-specific interactions are to be avoided or where a desired balance between non-specific and specific interactions must be achieved; and (c) Injectable or paintable carriers for delivering and / or protecting or shielding drugs, biomolecules (e.g., nucleic acids, peptides, proteins, polysaccharides), cells (e.g., pancreatic islets, cardiovascular cells, stem cells, T cells, blood cells), nanoparticles or microparticles (e.g., PLGA / drug preparations), micelles, liposomes, polymersomes, or other therapeutic species or drug delivery modalities in surgical applications, therapeutic applications, wound healing, and drug delivery preparations.
[0148] ZPS star hydrogels and microgels, and assemblies thereof, can be used as scaffolds, matrices, or substrates for the growth, maintenance, or proliferation of cells and tissues, where the cells and microgel constructs can be grown using any culture method or device, including any type of bioreactor, and can be derived from lineages including: (a) Pluripotent and multipotent stem and progenitor cells, including: (i) Embryonic stem cells (ESCs), tissue-derived stem cells (e.g., from skin, blood, or eye), hematopoietic stem and progenitor cells (HSPCs), mesenchymal stem cells, or induced pluripotent stem cells (iPSCs), derived from or purified from umbilical cord blood or bone marrow; (ii) genetically modified or transfected stem and progenitor cells, and (iii) cancer stem cells (CSCs); (b) Hematopoietic cells that typically circulate in human blood, including red blood cells (erythrocytes), white blood cells (leukocytes), and platelets (thrombocytes); (c) Immune cells and progenitor cells, or lineages differentiated therefrom, including: (i) CD8 surface glycoprotein-expressing T cells, including in particular naive cytotoxic T lymphocytes (CTLs) and lineages differentiated or activated therefrom (including central memory T cells); (ii) CD4 surface glycoprotein-expressing T cells, including in particular naive helper T lymphocytes and lineages differentiated or activated therefrom, including TH1, TH2, TH9, TH17, THC, Treg, and central memory (TCM) T cells; (iii) Regulatory T cells (Tregs) derived from any source (natural Tregs or induced Tregs) (or inducer Treg), (iv) natural killer T cells (NKT) cells; (v) chimeric antigen receptor T cells (CAR-T); (vi) genetically modified T cells; (d) B cells, dendritic cells, and other antigen-presenting cells (APCs) or immune cells not specifically listed above; (e) pancreatic islet cells or other insulin-producing cells and beta cells, useful in the treatment and management of diabetes; (f) Neural system cells and progenitor cells; (g) cardiovascular and progenitor cells; and (h) Cells useful in the fields of immunotherapy, regenerative medicine, hematological or malignant tumors, or cancer vaccines or treatments.
[0149] ZPS star hydrogels and microgels, and assemblies thereof, can be used as biocompatible materials, scaffolds, preparation components, or contact materials for clinical or military purposes in any manner to preserve or retain the biological function of cells or tissues, particularly cell types such as blood cells (e.g., platelets and red blood cells) that are difficult to preserve by conventional methods, for extended periods of time, at room or low temperatures, in whole blood or in storage solutions, with or without DMSO, glycerin, glycine betaine, or other osmolytes or cryoprotectants.
[0150] ZPS star hydrogels and microgels, and aggregates thereof, can be used to form objects, devices, and components such as implantable biosensors; wound care devices, adhesives, and sealants, contact lenses; dental implants; orthopedic devices such as artificial joints, bones, ligaments, and tendons; cardiovascular devices such as catheters, valves, vascular grafts, stents, LVADs, or rhythm management devices; gastroenterology devices such as feeding tubes, gastrointestinal clips, gastrointestinal sleeves, or gastric balloons; OB / Gyn devices such as implantable birth control devices or vaginal slings; nephrology devices such as anastomosis connectors or subdermal ports; nerve guidance devices. tubes), neurological surgical devices such as cerebrospinal fluid drains or shunts, dermatological devices such as skin repair devices, ophthalmic devices such as shunts, ENT devices such as stents, cochlear implants, tubes, shunts, or dilators, intraocular lenses; cosmetic implants such as breast implants, nasal implants, and cheek implants; neural implants such as neurostimulation devices, cochlear implants, and nerve conduits; hormone control implants such as blood glucose sensors and insulin pumps; implanted biosensors; access port devices; and tissue scaffolds, pulmonary valve devices such as valves or oxygenators for COPD management; radiological devices such as radiopaque or ultrasound opaque markers; or urological devices such as catheters or urethra prostheses.
[0151] In another embodiment, the present invention provides a substrate coated with ZPS star hydrogel or microgel or microgel aggregates. Exemplary substrates include objects, devices, and components such as implantable biosensors; wound care devices, adhesives, and sealants, contact lenses; dental implants; orthopedic devices such as artificial joints, bones, ligaments, and tendons; cardiovascular devices such as catheters, valves, vascular grafts, stents, LVADs, and / or rhythm management devices; gastroenterology devices such as feeding tubes, GI clips, GI sleeves, or gastric balloons; OB / Gyn devices such as implantable birth control devices or vaginal slings; nephrology devices such as anastomosis connectors or subdermal ports; neurosurgery devices such as nerve guidance tubes, cerebrospinal fluid drains, or shunts. devices, dermatological devices such as skin repair devices, ophthalmic devices such as shunts, ENT devices such as stents, cochlear implants, tubes, shunts, or dilators, intraocular lenses; cosmetic implants such as breast implants, nasal implants, and cheek implants; neural implants such as neurostimulation devices, cochlear implants, and nerve conduits; hormone control implants such as blood glucose sensors and insulin pumps; implanted biosensors; access port devices; and tissue scaffolds, pulmonary valve devices such as valves or artificial lungs for COPD management; radiological devices such as radiopaque or ultrasound opaque markers; or urological devices such as catheters or artificial urethras.
[0152] ZPS Polymer Nanoparticles and Microparticles In another aspect, the present invention provides nano- and microparticles comprising the ZPS polymers and copolymers of the present invention. The ZPS polymers and copolymers of the present invention can be used to form nano- and microparticles in the form of nano- and microgels, micelles, liposomes, and polymersomes. They can also be used to coat solid particles such as quantum dots, iron oxide, silica, and gold for therapeutic or diagnostic purposes. The ZPS polymers and copolymers of the present invention can be attached to nano- and microparticles by covalent and non-covalent bonds.
[0153] In certain embodiments, nanoscale particles are provided. The particles have a core with a plurality of ZPS polymers or copolymers grafted to or from the surface of the core. Exemplary particle cores include metals, metal oxides, ceramics, synthetic polymers, natural polymers, crystals, semiconductor materials, graphene, graphene oxide, iron oxide, silica, quantum dots, hydrogels, liposomes, micelles, carbon-based materials, or biomolecules.
[0154] ZPS Polymer and Copolymer Conjugates In a further aspect, the present invention provides ZPS polymer and copolymer conjugates. ZPS polymers can be attached to biomolecules (e.g., proteins / peptides, nucleic acids, and sugars), other macromolecules, and cells by graft-to or graft-from techniques to provide a variety of conjugates.
[0155] In certain embodiments, the ZPS polymer conjugate or copolymer conjugate is a ZPS polymer bioconjugate that comprises one or more ZPS polymers bound to a biomolecule.Suitable biomolecules include proteins, nucleic acids, glycoproteins, proteoglycans, and lipids.Suitable biomolecules include small molecule therapeutic agents (i.e., carbon-based therapeutic agents with a molecular weight of less than about 1000 g / mol, preferably less than about 800 g / mol).
[0156] Exemplary proteins include enzymes, signaling proteins, hemostatic and thrombosis proteins, vaccines, complement system proteins, and antibodies, functional fragments or characteristic portions thereof. Exemplary signaling proteins include hormones, cytokines, regulatory proteins, insulin, and PD-1 / PD-L1 / 2 inhibitors.
[0157] In certain of these embodiments, the ZPS polymer or copolymer conjugate is a ZPS polymer or copolymer bioconjugate that includes one or more ZPS polymers or copolymers attached to a modified biomolecule (e.g., a polymer-modified biomolecule). Examples of polymer-modified biomolecules include biomolecules modified with polyethylene glycol (PEG) polymers (e.g., the PEG moieties of such PEG-modified biomolecules may be in the polymer backbone or may be pendant from the polymer backbone). The polymer-modified biomolecule may include one or more ZPS polymers or copolymers. A representative example of further modification by attaching a polymer is described in Example 5.
[0158] In other embodiments, the ZPS polymer or copolymer conjugate is a ZPS polymer or copolymer bioconjugate comprising one or more ZPS polymers bound to a cell, virus, or bacteria.
[0159] The ZPS polymer or copolymer conjugates can be delivery vehicles. Exemplary delivery vehicles include micelles, liposomes, or polymersomes for therapeutic or diagnostic applications.
[0160] In certain embodiments, the present invention provides micelles, liposomes, polymersomes, or particles formed by self-assembly of copolymers or conjugated lipids of the present invention that include one or more ZPS polymers or copolymers.
[0161] In a further embodiment, the present invention provides a composition comprising a ZPS polymer or copolymer conjugate and a pharma- ceutically acceptable carrier or diluent. In certain embodiments, the ZPS polymers and copolymers of the present invention can be used as a carrier or diluent for the composition.
[0162] The preparation and immunogenicity of representative ZPS polymer-protein conjugates is described in Example 7.
[0163] ZPS polymer nanogels and nanocages In another aspect, the present invention provides ZPS polymer nanogels and nanocages. ZPS polymers can be used to provide nanogels that chemically entrap one or more other species, and nanocages that physically entrap one or more other species.
[0164] In certain embodiments, the present invention provides nanogels comprising one or more ZPS polymers or one or more ZPS copolymers for chemical encapsulation of contents.
[0165] In another embodiment, the present invention provides nanocages comprising one or more ZPS polymers or one or more ZPS copolymers for physically encapsulating contents.
[0166] Suitable contents (e.g., species) to be chemically entrapped by the nanogels or physically entrapped by the nanocages include biomolecules such as proteins, lipids, glycoproteins, cells, viruses, bacteria, and small molecules (e.g., therapeutic agents with a molecular weight of less than about 1000 g / mol, preferably 800 g / mol), or other biomolecules described herein.
[0167] In certain embodiments, the nanogel or nanocage comprises a ZPS polymer or copolymer and one or more therapeutic agents.
[0168] In other embodiments, the nanogel or nanocage comprises a ZPS polymer or copolymer and one or more diagnostic agents.
[0169] In further embodiments, the nanogel or nanocage comprises a ZPS polymer or copolymer, one or more therapeutic agents, and one or more diagnostic agents.
[0170] Non-zwitterionic phosphatidylserine monomers, polymers, copolymers, compositions, surfaces, and methods of preparation and use thereof It is understood that neutral phosphatidylserine (NPS) monomers, polymers, and copolymers (also referred to herein as non-zwitterionic phosphatidylserine (NZPS) monomers, polymers, and copolymers) are also within the scope of the present invention. Thus, in further aspects, the present invention provides non-zwitterionic phosphatidylserine (NZPS) monomers, NZPS polymers, and NZPS copolymers, methods of making NZPS monomers, NZPS polymers, and NZPS copolymers, compositions and materials comprising NZPS polymers and NZPS copolymers, and methods of using NZPS monomers, NZPS polymers, and NZPS copolymers.
[0171] As used herein, the term "non-zwitterionic phosphatidylserine monomer" or "NZPS monomer" refers to a phosphatidylserine monomer that is 2 -CH(-CH 2 OP(=O)(O - ))-CO 2 H and its ionic forms) of homopolymers or copolymers containing polymerizable monomers or pendant groups.
[0172] A representative NZPS monomer has the formula (VI):
[0173] [ka]
[0174] In certain embodiments, R 1 is hydrogen, fluorine, trifluoromethyl, cyano, C 1 -C 20 Alkyl (preferably C 1 -C 6 alkyl), and C 6 -C 12 aryl, X is O or NH, n is an integer from 1 to 20 (e.g., 1, 2, 3, 4, 5, or 6), and p is an integer from 1 to 20 (e.g., 1, 2, 3, 4, 5, or 6).
[0175] The term "non-zwitterionic phosphatidylserine polymer" or "NZPS polymer" refers to a polymer (ie, homopolymer or copolymer) having one or more pendant groups that contain a phosphatidylserine moiety, as described above.
[0176] NZPS polymers are prepared by polymerization of monomers of formula (VI), and NZPS copolymers are prepared by copolymerization of monomers of formula (VI) with comonomers. Such NZPS polymers (homopolymers, random copolymers, block copolymers) contain repeat units with pendant phosphatidylserine (PS) moieties as shown below.
[0177] [ka]
[0178] In certain embodiments, R 1 , X, n, and p are as described above for monomers of formula (VI), a is an integer from about 10 to about 500, and * indicates the point of attachment of this repeat unit to other repeat units in the polymer or copolymer, or an end group of the polymer.
[0179] NZPS monomers can be readily polymerized under standard polymerization conditions to provide NZPS polymers.
[0180] Thus, all of the descriptions provided herein relating to ZPS monomers, ZPS polymers, ZPS copolymers, compositions comprising ZPS polymers, surfaces comprising ZPS polymers, and methods of using ZPS monomers, polymers, and compositions are understood to apply equally to NZPS monomers, polymers, compositions, surfaces, and methods.
[0181] Example 2 describes the preparation and characterization of a representative NZPS according to the present invention.
[0182] The preparation and immunogenicity of representative NZPS polymer-protein conjugates is described in Example 7.
[0183] Described herein are PS-mimetic polymerizable (NZPS) monomers, polymers derived from such monomers, and polymers attached to biomolecules, macromolecules, small molecules, particles, implants, devices, surfaces, coatings, and hydrogels. Biocompatible immunosuppressive biomaterials include NZPS polymers, and derivatives and precursors thereof, for use with peptides, proteins, lipids, glycoproteins, macrobiomolecules (e.g., cells, viruses, bacteria, etc.), nanoparticles, microparticles, and small molecule drugs, all of which can be used for administration to the human body, including in conjunction with medical devices, prostheses, implanted materials (including dental), and organ grafts.
[0184] In one embodiment, polymerizable NZPS monomers and derivatives or precursors have the formula (VIII):
[0185] [ka]
[0186] During the ceremony, A, G, and I are functional groups that impart polymerizability to the monomer in certain embodiments, and are H, F, Cl, Br, I, SH, protected thiol, NH 2, -NH- (secondary amine), N=C=O, protected NCO, N=C=S, COOH, activated ester, aldehyde, COSH, C(=S)SH, OCOOH, OCOSH, OC(=S)OH, SC(=O)SH, SC(=S)SH, N(C=O)NH 2 , N(C=NH)NH 2 , N(C=S)NH 2 , δ-valerolactone, ε-caprolactone, CH 2 =CH-C(=O)-O-, CH 2 =CH-C(=O)-NH-, CH 2 =CH-C(=O)-S-, CN, CH 2 =C(CH 3 )-C(=O)-O-, CH 2 =C(CH 3 )-C(=O)-NH-, OH, azide, alkyne, C 6 -C 10 independently selected from an aryl group, a cyclic group (isobornyl, cyclohexyl, cyclopentyl), a fluoro (perfluorobutyl, perfluoroethyl) derivative, or none (absent); B, F, and H are each a group represented by the formula -(CH 2 ) x - independently selected; Ccis is selected from C, N, Si, or none (absent); and D is C(=O)(CH 2 ) x、 -(CH 2 ) x - is selected.
[0187] Also provided are methods for preparing such monomers, polymers prepared from such monomers, and methods for using such polymers to attach to or from nanoparticles, surfaces, coatings, and hydrogels, and their use to impart an immunosuppressive effect to such nanoparticles, surfaces, coatings, and hydrogels.
[0188] In another aspect, NZPS polymers and copolymers are provided. Such polymers and copolymers include repeat units. In certain embodiments, the repeat units of such polymers and copolymers have the formula (IX): 2 and R 3 (Repeating unit is R 2 and R 3 (It is believed that the polymers and copolymers do not include the aryl group, however the macromonomers may include it, and possibly the polymers and copolymers may also include it).
[0189] [ka]
[0190] The above formula is n repeating units -M 1 -(K 1 -ZK 2 ) j -M 2 -M 1 -(K 3 -XK 4 ) j -M 2 -, which has j repeat units -K 1 -ZK 2 - and j repeat units -K 3 -XK 4 -Including.
[0191] In the above formula, K 1 , K 2 , K 3 , and K 4 wherein each x is an integer independently selected from 0 to 20, a combination thereof, or none (when no substituent is present); -(CH 2 ) x -, -(CH(CN)) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x -, -C(=O)OC(=O)O(CH 2 )x -, -(CH 2 ) x -O-(CH 2 ) x - and -(CH 2 ) x -SS-(CH 2 ) x - independently selected; R 2 and R 3 are H, F, Cl, Br, I, OH, SH, protected thiols, NH 2 , -NH-(Secondary amine), N=C=O, N=C=S, COOH, COSH, C(=S)SH, OCOOH, OCOSH, OC(=S)OH, SC(=O)SH, SC(=S)SH, N(C=O)NH 2 , N(C=NH)NH 2 , N(C=S)NH 2 , δ-valerolactone moiety, ε-caprolactone moiety, CH 2 =CH-C(=O)-O-, CH 2 =CH-C(=O)-NH-, CH 2 =CH-C(=O)-S-, CN, CH 2 =C(CH 3 )-C(=O)-O-, CH 2 =C(CH 3 )-C(=O)-NH-, or none (when no substituent is present); n is an integer from 5 to about 10,000.
[0192] Each j is an integer of 1 to about 1,000.
[0193] M 1 and M. 2 In the formula, n is an integer of 1 to 20. 2 ) n -, -S-(CH 2 ) n -, -C(=O)-(CH 2 ) n -, -C(=S)-(CH 2 ) n -, -C(=NH)-(CH 2 ) n-, and -NH-(CH 2 ) n -; where each x is an integer independently selected from 0 to 20, a combination thereof, or none (when no substituents are present); -(CH 2 ) x -, -(CH(CN)) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x -, -C(=O)OC(=O)O(CH 2 ) x -, -(CH 2 ) x -O-(CH 2 ) x - and -(CH 2 ) x -SS-(CH 2 ) x - independently selected from the group consisting of; and Z and X are independently selected from the group consisting of the following formulae:
[0194] [ka]
[0195] In the formula, L is F, Cl, Br, I, SH, a protected thiol, NH 2 , -NH- (secondary amine), N=C=O, protected NCO, N=C=S, COOH, COSH, C(=S)SH, OCOOH, OCOSH, OC(=S)OH, SC(=O)SH, SC(=S)SH, N(C=O)NH 2 , N(C=NH)NH 2 , N(C=S)NH 2 , δ-vale Lactone, ε-caprolactone, CH 2 =CH-C(=O)-O-, CH 2 =CH-C(=O)-NH-, CH 2 =CH-C(=O)-S-, CN, CH 2 =C(CH 3 )-C(=O)-O-, CH 2 =C(CH3 )-C(=O)-NH-, OH, azide, alkyne, C 6 -C 10 independently selected from an aryl group, a cyclic group (isobornyl, cyclohexyl, cyclopentyl), a fluoro(perfluorobutyl, perfluoroethyl) derivative, or none; K is -(CH 2 ) x - independently selected; J is C(=O)(CH 2 ) x、 -(CH 2 ) x - selected from; and * indicates K as indicated 1 , K 2 , K 3 , and K 4 This is the attachment point.
[0196] As used herein, the term "about" refers to ±5 percent of the stated value.
[0197] The following examples are offered for the purpose of illustrating, but not limiting, the present invention. EXAMPLES
[0198] Working Example Example 1 Preparation and characterization of representative ZPS monomers In this example, the synthesis and purification of a representative polymerizable zwitterionic (ZPS) monomer is described.
[0199] A schematic of the synthesis process of the polymerizable ZPS monomers according to the present invention is shown below.
[0200] [ka]
[0201] Synthesis of 3-(tert-butoxy)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl(2-((2-(methacryloyloxy)ethyl)dimethylammonio)ethyl)phosphate (compound 3). N-Boc-Ser-OtBu (1.0 gm, 3.82 mmol) was dissolved in 30 ml of anhydrous benzene and the solution was cooled to 0° C. Next, triethylamine (0.62 mL, 4.6 mmol) was added followed by 2-chloro-2-oxo-1,3,2-dioxaphospholane 1 (0.42 mL, 4.6 mmol) in 10 mL of anhydrous benzene was added dropwise over 30 minutes and the reaction was then stirred at room temperature for an additional 3 hours. After completion of the reaction, diethyl ether was poured into the reaction mixture and the precipitated trimethylamine hydrochloride was removed by filtration. The filtrate was then concentrated under reduced pressure to give compound 2 as an oil, which was used in the next step without further purification. Compound 2 was redissolved in 30 mL of anhydrous acetonitrile and 2-(dimethylamino)ethyl methacrylate (1.45 mL, 8.8 mmol) was added. The reaction mixture was then heated to 55° C. The reaction mixture was then concentrated in vacuo and purified by flash column chromatography to give compound 3 in 42% yield. 1 H NMR (300 MHz, CDCl 3 )δ6.18(s,1H),5.67(s,1H),4.63-4.54(m,2H),4.35-4.14(m,3H),4.10-3.99(m,2H),3 .83-3.76(m,2H),3.40-3.27(m,2H),2.82(s,6H),1.97(s,3H),1.46(d,J=11.7Hz,18H).
[0202] Synthesis of a representative ZPS monomer (compound 4). Compound 3 (0.84 gm, 1.6 mmol) was dissolved in 5 mL of dichloromethane and 30 mL of trifluoroacetic acid was added. The reaction was stirred for 5 hours. After completion of the reaction, the reaction mixture was concentrated under vacuum to obtain a thick and viscous liquid. The crude product was then crystallized using MeOH:diethyl ether (1:15) to obtain the desired compound 4 as a white powder. 1H NMR (300 MHz, D 2 O)δ6.08(s,1H),5.69(s,1H),4.47-4.41(m,2H),4.26-4.23(m,2H),4.05-4.00(m,1H) ),3.87-3.84(m,2H),3.69-3.67(m,2H),3.50-3.45(m,2H),2.88(s,6H),1.84(s,3H).
[0203] Example 2 Preparation and characterization of representative neutral PS monomers In this example, the synthesis and purification of a representative polymerizable neutral PS (NZPS) monomer is described. A schematic of the synthesis process for this NZPS monomer is shown below.
[0204] [ka]
[0205] Synthesis of compound 5. N-Boc-Ser-OtBu (1.0 gm, 3.82 mmol) was dissolved in 30 ml of anhydrous benzene and the solution was cooled to 0° C. Triethylamine (0.62 mL, 4.6 mmol) was then added followed by 2-chloro-2-oxo-1,3,2-dioxaphospholane 1 (0.42 mL, 4.6 mmol) in 10 mL of anhydrous benzene was added dropwise over 30 minutes and the reaction was then stirred at room temperature for another 3 hours. After completion of the reaction, diethyl ether was poured into the reaction mixture and the precipitated trimethylamine hydrochloride was removed by filtration. The filtrate was then concentrated under reduced pressure to give compound 2 as an oil, which was used in the next step without further purification. Compound 2 was redissolved in 30 mL of anhydrous acetonitrile, to which sodium methacrylate (0.62 gm, 5.7 mmol) and 18-crown-6 ether (0.14 gm, 0.53 mmol) were added. The reaction mixture was then stirred at 55° C. for 72 hours. After reaction, the reaction product was filtered, concentrated under vacuum, and purified by flash column chromatography to obtain compound 5 in 71% yield. 1 H NMR (300 MHz, CDCl 3)δ6.15(s,1H),5.57(s,1H),4.41-4.27(m,2H),4.24-4.04(m,4H),3.86-3.78(m,1H),1.95(s,3H),1.46(d,J=5.4Hz,18H).
[0206] Synthesis of a representative neutral PS monomer (compound 6). Compound 5 (1.2 gm, 2.65 mmol) was dissolved in 5 mL of dichloromethane, to which 30 mL of trifluoroacetic acid was added. The reaction was stirred for 5 hours. After completion of the reaction, the reaction mixture was concentrated under vacuum to obtain a thick and viscous liquid. The crude product was then crystallized using MeOH:diethyl ether (1:20) to obtain the desired compound 6 as a white powder. 1 H NMR (300 MHz, D 2 O) δ6.11(s,1H),5.66(s,1H),4.34-4.15(m,5H),4.10-3.97(m,2H),1.85(s,3H).
[0207] Example 3 Non-fouling properties of representative NZPS and ZPS hydrogels In this example, the non-fouling properties of representative NZPS and ZPS hydrogels are described.
[0208] Preparation of ZPS hydrogel ZPS hydrogels were fabricated by bulk photopolymerization using a hydrogel aqueous solution containing ZPS monomers (0.67 g Milli-Q water, 330 mg), the crosslinker N,N' methylene bis(acrylamide) (1 wt%, 3.3 mg), and the photoinitiator 2-hydroxy-2-methylpropiophenone (0.33 mg). The hydrogel aqueous solution was placed between two glass slides with a 0.5 mm thick polytetrafluoroethylene spacer in between, and then photopolymerized for 30 min at room temperature. After polymerization, the hydrogels were removed from the mold and immersed in PBS for 3 days to remove unreacted chemicals and obtain a well-hydrated hydrogel network. The phosphate-buffered saline was replaced every 12 h. The same protocol was followed to prepare MPC and NZPS hydrogels with the same crosslink density.
[0209] Fibrinogen adsorption test Hydrated MPC, NZPS, and ZPS hydrogels were punched into disks with a diameter of 5 mm using a biopsy punch. The hydrogel disks were placed in a 24-well plate and incubated with 1 mL of 1 mg / mL fibrinogen (in PBS buffer) for 1 h, followed by washing five times with pure PBS buffer. The hydrogel disks were then transferred to new wells and incubated with 1 mL of horseradish peroxidase (HRP)-labeled anti-fibrinogen (1 μg / mL) (in PBS buffer) for 1 h. Then, after washing five times with pure PBS buffer, all hydrogel disks were transferred to new wells. Next, 1 mL of 1 mg / mL o-phenylenediamine (OPD) (containing 0.03% hydrogen peroxide in 0.1 M citrate phosphate solution, pH 5.0) was added. After 15 min of incubation, the enzymatic reaction was stopped by adding the same volume of 1 M HCl. The same procedure was performed on control tissue culture polystyrene (TCPS) disks with the same surface area. Absorbance values at 492 nm were recorded using a plate reader and normalized to that of a TCPS sample. Data from triplicate samples were averaged.
[0210] After 1 h of incubation in a highly concentrated fibrinogen solution (10 mg / mL), the ZPS hydrogel discs exhibited excellent non-fouling properties, with 84.4% less adsorbed fibrinogen than the TCPS discs, whereas the NZPS hydrogel discs showed a smaller reduction in adsorbed fibrinogen (41%) compared to the TCPS discs (Figure 1).
[0211] Example 4 Immunosuppressive effects of representative NZPS and ZPS nanogels In this example, the immunosuppressive effects of representative NZPS and ZPS nanogels are described.
[0212] Preparation of MPC, NZPS, and ZPS nanogels AOT (sodium bis(2-ethylhexyl) sulfosuccinate, 237 mg) and Brij30 (poly(ethylene glycol) dodecyl ether, 459 mg) were added to a 20 mL glass vial with a stir bar. The vial was sealed with a Teflon-lined septum-equipped cap and purged with dry nitrogen for 10 minutes. Nitrogen-deoxygenated hexane (10 mL) was then added to the vial with vigorous stirring. As the aqueous phase, the monomers (MPC, NZPS, ZPS) and crosslinker (MBA) were dissolved in PBS buffer (pH 7.4, 250 μL) in a molar ratio of 95%:5%. Dry nitrogen was bubbled through the monomer solution for 2 minutes, after which the aqueous phase was slowly dripped into the organic continuous phase. The vial was sonicated to form a stable nanoemulsion. Then, 20% (w / v) ammonium persulfate solution (in deionized water) (10 μL) was added to the emulsion. After 5 min, polymerization was initiated by adding tetramethylethylenediamine (TEMED, 6 μL) and maintained at 4 °C under high speed magnetic stirring. After 2 h of reaction, the organic solvent was removed by rotary evaporation and the nanogel was precipitated and washed three times with THF. The nanogel was resuspended in PBS buffer and purified with a centrifugal filter with a molecular weight cutoff of 100 KDa to remove unreacted monomer and crosslinker.
[0213] Preparation of MPC, NZPS, and ZPS nanogels encapsulating FITC-BSA AOT (sodium bis(2-ethylhexyl) sulfosuccinate, 237 mg) and Brij30 (poly(ethylene glycol) dodecyl ether, 459 mg) were added to a 20 mL glass vial with a stir bar. The vial was sealed with a Teflon-lined septum-equipped cap and purged with dry nitrogen for 10 min. Nitrogen-deoxygenated hexane (10 mL) was then added to the vial with vigorous stirring. As the aqueous phase, FITC-BSA, monomers (MPC, NZPS, ZPS), and crosslinker (MBA) were dissolved in PBS buffer (pH 7.4, 250 μL) in a molar ratio of 95%:5%. Dry nitrogen was bubbled through the monomer solution for 2 min, after which the aqueous phase was slowly dripped into the organic continuous phase. The vial was sonicated to form a stable nanoemulsion. Then, 20% (w / v) ammonium persulfate solution (in deionized water) (10 μL) was added to the emulsion. After 5 min, polymerization was initiated by adding tetramethylethylenediamine (TEMED, 6 μL) and maintained at 4 °C under high-speed magnetic stirring. After 2 h of reaction, the organic solvent was removed by rotary evaporation, and the nanogels were precipitated and washed three times with THF. The nanogels were resuspended in PBS buffer and purified with a 100 KDa centrifugal filter to remove free FITC-BSA, unreacted monomer, and crosslinker.
[0214] Immunosuppressant effects RAW264.7 cells (10 5Cells (cells / well) were exposed to various concentrations (10, 25, 50, 100, 200, 1000 μg / ml) of MPC, NZPS, or ZPS nanogel solutions for 18 h. The cells were then stimulated with LPS solution (100 ng / mL) for another 48 h, after which the cells were centrifuged at 300 g for 10 min and the supernatant medium was collected for cytokine (TNF-α) analysis by ELISA. As shown in Figure 2A, the effects of NZPS and ZPS on TNF-α levels were both dose-dependent, and the inhibition of TNF-α by NZPS began at a relatively low concentration, suggesting that it has a stronger immunosuppressive effect than ZPS.
[0215] Annexin V Blockade To confirm that the immunosuppressive effects of NZPS and ZPS are due to the eat-me signaling mediated by these PS heads, we investigated the effect of MPC, NZPS, or ZPS on the immune system. The nanogel solutions (100 μg / ml) were pre-incubated with various concentrations (0, 10, 25, 50, 100, 200 μg / ml) of Annexin V (a protein that has high affinity for the PS group and can inhibit the eat-me signal) for 6 hours. Then, RAW264.7 macrophages (10 5 Cells were treated with 100 μg / well of ZPS nanogel (100 ng / mL) for 18 h, followed by stimulation with LPS (100 ng / mL) for 48 h. The level of TNF-α secretion in the supernatant was measured by ELISA kit. As shown in Figure 2B, with increasing concentration of annexin V, the TNF-α secretion-reducing effect of NZPS and ZPS nanogel decreased, indicating that the immunosuppressive effect was effectively blocked. Notably, ZPS nanogel was relatively less sensitive to the blocking effect of annexin V, which is probably due to the non-fouling property of ZPS, which reduces the affinity of PS functional groups in ZPS with their receptors to some extent. This also explains the weaker immunosuppressive effect of ZPS than that of NZPS.
[0216] Cellular uptake RAW264.7 macrophages (105 1000 cells / well) were incubated with MPC, NZPS, and ZPS nanogels encapsulating FITC-BSA for 30, 60, 120, and 180 min, after which the cells were washed and lysed, and the recovered fluorescence was detected. As shown in Fig. 2C, MPC had the lowest cellular uptake due to its excellent non-fouling properties, while NZPS nanogels were rapidly taken up by macrophages due to the eat-me signaling. Compared with NZPS, ZPS was taken up slowly due to its non-fouling properties and low affinity for the receptor. These results suggest that ZPS may be able to simultaneously achieve effective immunosuppression and good non-fouling performance due to its inherent zwitterionic structure.
[0217] Example 5 Representative poly(ZPS)- and poly(NZPS)-containing bioconjugates In this example, representative bioconjugates according to the present invention are described. In certain embodiments, the representative bioconjugates include ZPS polymer components. In other embodiments, the representative bioconjugates include NZPS polymer components.
[0218] In this example, the bioconjugate is an enzyme conjugate. An exemplary enzyme is uricase. The polymer is covalently attached to the enzyme either directly or via a linker suitable for connecting the polymer to the enzyme.
[0219] In the representative bioconjugates shown below, the bioconjugate further comprises a poly(ethylene glycol) (PEG) moiety. In certain embodiments, such bioconjugates comprise PEG in a linker interposed between the enzyme and the PS polymer. In other embodiments, such bioconjugates comprise PEG as a pendant group from the polymer backbone (e.g., from the polymerization of PEGMA).
[0220] Preparation and characterization of representative poly(ZPS)-block-poly(PEGMA) block copolymer-containing bioconjugates Synthesis of poly(ZPS)-block-poly(PEGMA) block copolymers with terminal thiol groups. The block copolymers are prepared by reversible addition-fragmentation chain transfer (RAFT) polymerization. In general, the polymerization of ZPS monomer (6.7 g) is initiated by azobisisobutyronitrile (AIBN, 18 mg) in the presence of 2-(dodecylthiocarbonothioylthio)-2-methylpropionic acid (100 mg) as a chain transfer agent (CTA). After 12 hours of reaction, the polymerization is stopped and the resulting polymer, poly(ZPS)-CTA, is purified by dialysis. Poly(ZPS)-CTA is then fused to the macromolecule CT A is used to polymerize PEGMA monomer (molar ratio, CTA / PEGMA=1 / 50). After precipitation in excess ether, the poly(ZPS)-block-poly(PEGMA)-CTA block copolymer is further purified by dialysis and lyophilization. Then, the CTA moiety of the block copolymer is converted to a thiol group using a mixed solution of hexylamine and triethylamine.
[0221] Preparation of poly(ZPS)-block-poly(PEGMA)-uricase conjugates First, the amine groups of uricase are converted to maleimide groups using the bifunctional crosslinker BMPS (N-maleimidopropyl-oxysuccinimide ester). Then, the activated uricase (10 mg) is mixed with poly(ZPS)-block-poly(PEGMA) copolymer (300 mg) bearing terminal thiol groups in 4 ml of PBS. The poly(ZPS)-block-poly(PEGMA)-uricase conjugate is purified by diafiltration to remove excess polymer and unreacted uricase.
[0222] Preparation and characterization of bioconjugates containing representative poly(ZPS) and poly(PEGMA) polymers Synthesis of poly(ZPS) with terminal thiol groups. The block copolymer is prepared by reversible addition-fragmentation chain transfer (RAFT) polymerization. Generally, the polymerization of ZPS monomer (6.7 g) is initiated by azobisisobutyronitrile (AIBN, 18 mg) in the presence of 2-(dodecylthiocarbonothioylthio)-2-methylpropionic acid (100 mg) as CTA. After reacting for 12 hours, the polymerization is stopped and the resulting polymer, poly(ZPS)-CTA, is purified by dialysis. Then, the CTA moiety of poly(ZPS)-CTA is converted to a thiol group using a mixed solution of hexylamine and triethylamine.
[0223] Synthesis of poly(PEGMA) with terminal thiol groups. Polymerization of PEGMA (5 g) is initiated by azobisisobutyronitrile (AIBN, 18 mg) in the presence of 2-(dodecylthiocarbonothioylthio)-2-methylpropionic acid (100 mg) as a chain transfer agent (CTA). After reacting for 12 hours, the polymerization is stopped and the resulting polymer, poly(PEGMA)-CTA, is purified by dialysis. The CTA moieties of poly(PEGMA)-CTA are then converted to thiol groups using a mixed solution of hexylamine and triethylamine.
[0224] Preparation of bioconjugates containing poly(ZPS) and poly(PEGMA). First, the amine groups of uricase are converted to maleimide groups using the bifunctional crosslinker BMPS (N-maleimidopropyl-oxysuccinimide ester). Then, the activated uricase (10 mg) is mixed with poly(ZPS) (100 mg) (in 4 ml PBS) bearing terminal thiol groups. The poly(ZPS)-uricase conjugate is purified by diafiltration to remove excess polymer and unreacted uricase. The second conjugation step is performed by mixing poly(PEGMA) bearing terminal thiol groups with poly(ZPS)-uricase. The poly(ZPS) and poly(PEGMA) modified uricase are purified by diafiltration to remove excess polymer.
[0225] The representative bioconjugate described in this example has the following structure:
[0226] [ka]
[0227] [ka]
[0228] [ka]
[0229] Example 6 Immunogenicity of Representative Neutral PS-PEG Bioconjugates In this example, the immunogenicity of a representative neutral PS-PEG bioconjugate is compared to a representative PEG-uricase.
[0230] PEG-uricase and PS mimetic polymer-PEG-uricase are administered intravenously into the tail vein of rats at a dose of 25 U / kg body weight. The administration of uricase samples is repeated five times with one week between immunizations. At the end of the fifth week (day 35), all rats are euthanized. The rats are sacrificed and blood collected by cardiac puncture is directly used for ELISA testing. In the ELISA testing, coated uricase is used as an antigen to detect anti-uricase antibodies, and BSA-PEG conjugate is required to detect anti-PEG antibodies.
[0231] As the first step of the direct ELISA test, 100 μL of antigen solution (protein concentration 10 μg / mL) prepared by dissolving in coating buffer (0.1 M sodium carbonate buffer, pH 10.5) is used to coat each well of a 96-well plate. After coating overnight at 4° C., the antigen solution is removed by washing the plate five times with PBS buffer (pH 7.4), and then filled with blocking buffer (1% BSA solution in 0.1 M Tris buffer, pH 8.0) and incubated at room temperature for 1 hour, after which the blocking buffer is removed. Then, all wells are washed with PBS buffer. The wells are washed five more times. Serial dilutions of rat serum in PBS buffer containing 1% BSA are then added to the plate (100 μL / well) and incubated at 37° C. for 1 h, after which the rat serum is removed and all wells are washed five times with PBS buffer. Goat anti-rat IgM or IgG (HRP-labeled, Bethyl Laboratories) is then added as a secondary antibody to each well and incubated at 37° C. for another 1 h. All wells are then washed five times with PBS buffer, followed by incubation with 3,3',5,5'-tetramethylbenzidine (TMB; Bethyl Laboratories), a substrate for HRP. Add 100 μL / well of Stop Solution (0.2 M NaCl, 100 mM NaCl, 100 mM Mg ... 2 SO 4 ) 100 μL is added to each well. The absorbance at 450 nm (signal) and 570 nm (background) is recorded using a microplate reader. Serum from rats not administered uricase samples is used as a negative control for all ELISA detections.
[0232] Rat spleens were harvested and strained through a 100 μm cell strainer (Fisherbrand TM) to separate splenocytes. The rat splenocytes from each group are stained with anti-rat MHCII and CD86 antibodies (eBioscience) and then analyzed by flow cytometry. To test T cell activation, the rat splenocytes from each group are plated in 12-well plates (10 6 The cells are cultured in 2 wells (1 mg / ml each) and then stimulated again with PEG-uricase and PS-mimetic polymer-PEG-uricase (1 mg / ml), respectively. In parallel, splenocytes from each rat are cultured in two wells. After 72 hours, cell culture medium is collected from each well and IL-4 is quantified using an IL-4 Rat ELISA kit (Life Technologies).
[0233] Example 7 Immunogenicity of representative ZPS, neutral PS, and PC bioconjugates In this example, the immunogenicity of representative bioconjugates is described. The bioconjugates are uricase conjugates. Uricase conjugates were prepared by covalently attaching (a) zwitterionic PS (ZPS) polymers, (b) neutral non-zwitterionic (NZPS) polymers, or (c) phosphatidaylcholine (PC) (MPC) polymers to the uricase surface.
[0234] Briefly, AOT (120 mg) and Brij30 (230 mg) were added to a 20 mL glass vial with a stir bar. The vial was sealed with a Teflon-lined septum-equipped cap and purged with dry nitrogen for 10 min. Nitrogen-deoxygenated hexane (5 mL) was then added to the vial under vigorous stirring. As the aqueous phase, uricase (1 mg) was dissolved in HEPES buffer (pH 8.5, 125 μL), to which ZPS monomer (50 mg) was added and dissolved. Dry nitrogen was bubbled through the monomer / protein solution for 2 min, after which the aqueous phase was slowly dripped into the organic continuous phase. The vial was sonicated to form a stable microemulsion. A 20% (w / v) APS solution (in Milli-Q water) (10 μL) was then added to the emulsion. After 5 min, polymerization was initiated by adding TEMED (6 μL) and maintained at 4° C. under high-speed magnetic stirring. After 2 h of reaction, the organic solvent was removed by rotary evaporation, and the ZPS-uricase conjugate was precipitated and washed three times with THF. The ZPS-uricase conjugate was resuspended in PBS buffer and purified by high-resolution size-exclusion chromatography (Sephacryl S-500HR) to remove free uricase. Finally, the conjugate was washed and concentrated three times with PBS (pH 7.4) using a centrifugal filter with a molecular weight cutoff of 100 kDa.
[0235] The structure of the conjugate is shown diagrammatically below.
[0236] [ka]
[0237] [ka]
[0238] For in vitro immunogenicity studies, DC2.4 dendritic cells (10 5Cells (cells / well) were incubated with PBS (blank control), native uricase, ZPS-uricase, NZPS-uricase, and MPC-uricase conjugate (2mU / mL) for 72 hours. At the end of the incubation period, cells were centrifuged at 300g for 10 minutes and the supernatant medium was collected for cytokine (TGF-beta) analysis by ELISA. Cells were harvested and washed twice with ice-cold sterile phosphate-buffered saline. Cells were labeled with anti-CD40-FITC or anti-CD80-PE and analyzed using flow cytometry. As shown in Figure 3A and Figure 3B, exposure to native uricase resulted in increased expression of costimulatory markers CD40 and CD80 (Figure 3A) and consequently a decrease in immature dendritic cells (Figure 3B). On the other hand, MPC-uricase, NZPS-uricase, and ZPS-uricase have reduced effects on stimulating dendritic cell activation. The effect of PS-uricase was the smallest, followed by ZPS-uricase. Measurement of TGF-beta, a typical immunosuppressive cytokine marker (Figure 3C), suggests that MPC-uricase had no effect on the level of TGF-beta, whereas both NZPS-uricase and ZPS-uricase have a significant effect of upregulating TGF-beta secretion.
[0239] For in vivo immunogenicity studies, ZPS-uricase, NZPS-uricase, and MPC-uricase conjugates were administered intravenously to the tail vein of mice at a dose of 25 U / kg body weight. The administration of uricase samples was repeated three times with a one-week interval between administrations. Blood of the mice was collected at various time points (0, 6 h, 24 h, 48 h, and 72 h) and Amplex was administered. TM The amount of uricase remaining in the blood was estimated by measuring the enzyme activity using a uric acid / uricase kit. At the end of the third week (day 21), all mice were euthanized. The mice were sacrificed and blood collected by cardiac puncture was used directly for ELISA testing.
[0240] As the first step of the direct ELISA test, 100 μL of antigen solution (protein concentration 10 μg / mL) prepared by dissolving in coating buffer (0.1 M sodium carbonate buffer, pH 10.5) is used to coat each well of a 96-well plate. After coating overnight at 4° C., the antigen solution is removed by washing the plate five times with PBS buffer (pH 7.4), and then filled with blocking buffer (1% BSA solution in 0.1 M Tris buffer, pH 8.0) and incubated at room temperature for 1 hour, after which the blocking buffer is removed. Then, all wells are washed five more times with PBS buffer. Subsequently, serial dilutions of mouse serum in PBS buffer containing 1% BSA are added to the plate (100 μL / well) and incubated at 37° C. for 1 hour, followed by removing the mouse serum and washing all wells five times with PBS buffer. Next, goat anti-rat IgM or IgG (HRP-labeled, Bethyl Laboratories) is added to each well as a secondary antibody and incubated at 37° C. for another 1 hour. Subsequently, all wells were washed five times with PBS buffer, and then 3,3',5,5'-tetramethylbenzidine (TMB; Bethyl) Add 100 μL / well of Stop Solution (0.2 M NaCl, 100 mM NaCl, 100 mM Mg ... 2 SO 4 ) is added to each well. The absorbance at 450 nm (signal) and 570 nm (background) is recorded using a microplate reader. Serum from mice not administered uricase samples is used as a negative control for all ELISA detections. Spleens from mice are also harvested on day 21 and strained through a 100 μm cell strainer (Fisherbrand TM Splenocytes were isolated using a 30-mL ELISA kit (Figure 1). Splenocytes from each group of mice were cultured in the presence of native uricase, MPC-uricase, NZPS-uricase, or ZPS-uricase for 72 hours, and then stained with anti-CD4-PE, anti-CD25-FITC, and anti-Foxp3-Percep antibodies for flow cytometry analysis.
[0241] As shown in Figures 4A and 4B and Table 1, uricase conjugated to MPC, an inactive zwitterionic polymer, resulted in accelerated blood clearance (ABC) after three doses.
[0242] [Table 1]
[0243] Unfolding with anti-uricase or anti-conjugate antibodies (Figures 4C and 4D) can explain the ABC phenomenon that occurred in the case of native uricase and MPC-uricase conjugate. Meanwhile, both zwitterionic PS (ZPS) and non-zwitterionic PS (NZPS) polymers can suppress the immune response that can be elicited by the immunogenic protein carrier (uricase). Such immunosuppressive effect leads to the absence of anti-conjugate antibodies (Figures 4C and 4D), which in turn maintains the circulation time of uricase conjugates after repeated administration (Table 1). The circulation time of NZPS-uricase was significantly shorter than that of ZPS-uricase, indicating that the "eat-me" signal of the PS head group of NZPS caused the rapid clearance, which is unfavorable for prolonging the residence time of the protein in vivo. Meanwhile, the circulation time of ZPS-uricase is comparable to that of MPC-uricase, indicating that ZPS, like other zwitterionic materials, can prolong the circulation time of proteins while retaining the immunosuppressive effect of PS, thus inhibiting the immunogenicity of proteins. Thus, ZPS has the unique property of simultaneously achieving a long circulation time and low immunogenicity, making it particularly suitable for nanoparticles (e.g., protein conjugates, liposomes, micelles, and solid nanoparticles such as gold, quantum dots, silica, and iron oxide nanoparticles). Characterization of mouse splenocytes also confirmed that NZPS-uricase and ZPS-uricase conjugates could upregulate the expression of T-regene cells (Figures 4E and 4F), explaining the phenomenon that they avoid undesirable immune responses.
[0244] While exemplary embodiments have been illustrated and described, it will be understood that these can be varied in various ways without departing from the spirit and scope of the invention. The embodiments of the invention in which an exclusive property or right is claimed are defined as follows:
Claims
1. A particle having microscale or nanoscale dimensions, the particle comprising one or more zwitterionic phosphatidylserine polymers attached to the particle.
2. The particle of claim 1 , wherein the particle has microscale dimensions.
3. The particle of claim 1 , wherein the particle has nanoscale dimensions.
4. The particle according to any one of claims 1 to 3, wherein the particle is a biomolecule.
5. The particle of claim 4 , wherein the biomolecule is a protein, a nucleic acid, a glycoprotein, a lipid, or a proteoglycan.
6. 5. The particle of claim 4, wherein the biomolecule is a protein selected from an enzyme, a signaling protein, a hemostatic or thrombosis protein, a vaccine, a complement system protein, or an antibody or a functional fragment or characteristic portion thereof.
7. The particle of claim 4 , wherein the biomolecule is a small molecule therapeutic agent.
8. The particle of any one of claims 1 to 3, wherein the particle is a drug delivery vehicle.
9. The particle of claim 8 , wherein the drug delivery vehicle is a micelle, liposome, or polymersome.
10. The particle according to any one of claims 1 to 3, wherein the particle is a cell, a virus, or a bacterium.
11. The particle according to any one of claims 1 to 3, wherein the particle is a hydrogel.
12. The particle of claim 11 , wherein the hydrogel is a microgel or a nanogel.
13. 4. The particle of any one of claims 1 to 3, wherein the particle is a metal, a metal oxide, a ceramic, a synthetic polymer, a natural polymer, a crystal, a semiconductor material, graphene, graphene oxide, iron oxide, or silica, or a quantum dot.
14. The particle of any one of claims 1 to 13, wherein the one or more zwitterionic phosphatidylserine polymers are grafted from the particle.
15. The particle of any one of claims 1 to 13, wherein the one or more zwitterionic phosphatidylserine polymers are grafted to the particle.
16. The one or more zwitterionic phosphatidylserine polymers may have the formula: [Formula 1] During the ceremony, * indicates the point of attachment of this repeat unit to another repeat unit in the polymer or copolymer, or an end group of a polymer or copolymer; B is the polymer backbone; L 2 wherein each x is an integer independently selected from 1 to 20; 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x -, -C(=O)OC(=O)O(CH 2 ) x -, -(CH 2 ) x -O-(CH 2 ) x - and -(CH 2 ) x -S-S-(CH 2 ) x - is a linker group selected from R 2 and R 3 is hydrogen, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; m is an integer from 1 to 20; p is an integer from 1 to 20; and n is an integer from about 10 to about 500. The particle according to any one of claims 1 to 13, having a repeating unit of the formula:
17. The one or more zwitterionic phosphatidylserine polymers may have the formula: [chemical 2] During the ceremony, * indicates the point of attachment of this repeat unit to another repeat unit in the polymer or copolymer, or an end group of a polymer or copolymer; R 1 is hydrogen, fluorine, trifluoromethyl, cyano, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; R 2 and R 3 is hydrogen, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; R 4 and R 5 is a polymerized residue of a polymerizable functional group; L is C or Si; L 2 wherein each x is an integer independently selected from 1 to 20; 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x -, -C(=O)OC(=O)O(CH 2 ) x -, -(CH 2 ) x -O-(CH 2 ) x- and -(CH 2 ) x -S-S-(CH 2 ) x - is a linker group selected from L 3 and L 4 wherein each x is an integer independently selected from 0 to 20; 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x -, -C(=O)OC(=O)O(CH 2 ) x -, -(CH 2 ) x -O-(CH 2 ) x - and -(CH 2 ) x -S-S-(CH 2 ) x - independently selected from; m is an integer from 1 to 20; p is an integer from 1 to 20; and n is an integer from about 10 to about 500. The particle according to any one of claims 1 to 13, having a repeating unit of the formula:
18. The one or more zwitterionic phosphatidylserine polymers may have the formula: [C3] During the ceremony, * indicates the point of attachment of this repeat unit to another repeat unit in the polymer or copolymer, or an end group of a polymer or copolymer; R 1 is hydrogen, fluorine, trifluoromethyl, cyano, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; R 2 and R 3 is hydrogen and C 1-C 6 independently selected from alkyl; X is O or NH; n is an integer from 1 to 20; m is an integer from 1 to 20; p is an integer from 1 to 20; and a is an integer from about 10 to about 500 The particle according to any one of claims 1 to 13, having a repeating unit of the formula:
19. A method for imparting immunosuppressive properties to a particle, the method comprising covalently attaching one or more zwitterionic phosphatidylserine polymers to the particle.
20. The surface of a substrate having one or more zwitterionic phosphatidylserine polymers covalently attached thereto.
21. A particle having microscale or nanoscale dimensions, comprising one or more neutral (non-zwitterionic) phosphatidylserine polymers covalently attached to said particle.
22. A method for imparting immunosuppressive properties to a particle, comprising covalently attaching one or more neutral (non-zwitterionic) phosphatidylserine polymers to the particle.
23. The surface of a substrate having one or more neutral (non-zwitterionic) phosphatidylserine polymers covalently attached thereto.
24. A ZPS monomer comprising a polymerizable moiety covalently linked to a zwitterionic phosphatidylserine moiety.
25. ZPS monomer having the formula: [C4] During the ceremony, R 1 is hydrogen, fluorine, trifluoromethyl, cyano, C 1 -C 20 Alkyl, and C 6 -C 12aryl; R 2 and R 3 is hydrogen, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; R 4 and R 5 are independently selected from functional groups suitable for polymerization by addition, condensation, or free radical polymerization; L is C or Si; L 2 represents -(CH 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x - independently selected from; L 3 and L 4 wherein each x is an integer independently selected from 0 to 20; 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x -, -C(=O)OC(=O)O(CH 2 ) x -, -(CH 2 ) x -O-(CH 2 ) x - and -(CH 2 ) x -S-S-(CH 2 ) x - independently selected from; m is an integer from 1 to 20; and p is an integer from 1 to 20.
26. ZPS monomer having the formula: [C5] During the ceremony, R 1is hydrogen, fluorine, trifluoromethyl, cyano, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; R 2 and R 3 is hydrogen and C 1 -C 6 independently selected from alkyl, X is O or NH; n is an integer from 1 to 20; m is an integer from 1 to 20; and p is an integer from 1 to 20.
27. A ZPS polymer or copolymer having repeating units, wherein one or more of the repeating units contains a zwitterionic phosphatidylserine moiety.
28. A ZPS polymer or copolymer having repeat units of the formula: [C6] During the ceremony, * indicates the point of attachment of this repeat unit to another repeat unit in the polymer or copolymer, or an end group of a polymer or copolymer; B is the polymer backbone; L 2 is a linker group connecting the ZPS moiety to the backbone, representative groups being -(CH 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x -, -C(=O)OC(=O)O(CH 2 ) x -, -(CH 2 ) x -O-(CH 2 ) x - and -(CH 2 ) x-S-S-(CH 2 ) x - includes; R 2 and R 3 is hydrogen, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; m is an integer from 1 to 20; p is an integer from 1 to 20; and n is an integer from about 10 to about 500.
29. A ZPS polymer or copolymer having repeat units of the formula: [C7] During the ceremony, * indicates the point of attachment of this repeat unit to another repeat unit in the polymer or copolymer, or an end group of a polymer or copolymer; R 1 is hydrogen, fluorine, trifluoromethyl, cyano, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; R 2 and R 3 is hydrogen, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; R 4 and R 5 are independently selected from the polymerizable residue of a functional group suitable for polymerization by addition, condensation, or free radical polymerization; L is C or Si; L 2 represents -(CH 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x - independently selected from; L 3 and L 4 wherein each x is an integer independently selected from 0 to 20; 2 ) x -, -C(=O)NH(CH 2 ) x -, -C(=O)O(CH 2 ) x -, -C(=O)OC(=O)O(CH 2 ) x -, -(CH 2 ) x -O-(CH 2 ) x - and -(CH 2 ) x -S-S-(CH 2 ) x - independently selected from; m is an integer from 1 to 20; p is an integer from 1 to 20; and n is an integer from about 10 to about 500.
30. A ZPS polymer or copolymer having repeat units of the formula: [C8] During the ceremony, * indicates the point of attachment of this repeat unit to another repeat unit in the polymer or copolymer, or an end group of a polymer or copolymer; R 1 is hydrogen, fluorine, trifluoromethyl, cyano, C 1 -C 20 Alkyl, and C 6 -C 12 aryl; R 2 and R 3 is hydrogen and C 1 -C 6 independently selected from alkyl; X is O or NH; n is an integer from 1 to 20; m is an integer from 1 to 20; p is an integer from 1 to 20; and a is an integer from about 10 to about 500.
Citation Information
Patent Citations
Emulsion as contrast medium and its application
JP1999193247A
Intra-cellular information transferring molecule production signal induction functional polymer and synthesis method thereof
JP2015096567A
Immunosuppressant materials and related methods
JP7534782B2
